Archive for May, 2014

Bristol-Myers Squibb ($BMY): Leading Risk Taker on a estimated $1.3 Billion Committed to Fund 78 currently known Clinical Trials which will enroll 19,000 Cancer Patients

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Human Immune System in Health and in Disease, Innovation in Immunology Diagnostics on May 29, 2014| Leave a Comment »

Bristol-Myers Squibb ($BMY): Leading Risk Taker on a estimated $1.3 Billion Committed to Fund 78 currently known Clinical Trials which will enroll 19,000 Cancer Patients

Reporter: Aviva Lev-Ari, PhD, RN

http://www.asco.org/

http://www.asco.org/meetings

American Society of Clinical Oncology — History

ASCO 50th Annual Meeting: Science & Society

VIEW VIDEO

http://am.asco.org/

May 30-June 3, 2014

McCormick Place
Chicago, Illinois

ASCO was founded in 1964 by a small group of physician members of the American Association of Cancer Research (AACR) who recognized the need for the creation of a separate society dedicated to issues unique to clinical oncology.

Below, explore highlights of ASCO’s past through a series of in-depth articles. You can also experience the history of the Society through video vignettes from the people who believed in ASCO from the beginning and learn about ASCO’s Founders and Past Presidents.

History Article Series

The Journal of Clinical Oncology (September 18, 2008): This article chronicles the 21-year history of the Journal of Clinical Oncology, the Society’s flagship publication and the foremost peer-reviewed journal in the field.
Developing the First Scientific Meeting (April 1, 2005): This article examines the decision to develop a scientific oncology meeting with a clinical focus and the planning process for what would become the Society’s first Annual Meeting.
ASCO’s Transition to Self-Management (January 1, 2005): This article examines the establishment of ASCO Headquarters and the Society’s growth from a volunteer-based professional organization to a fully staffed, internationally recognized authority on clinical oncology.
Creating the ASCO Brand (July 1, 2004): This article examines how the Society’s now familiar name was once a matter of spirited debate among its founding members — a notion that might seem puzzling to current members.
The ASCO Annual Meeting (April 1, 2004): This article examines how, In 1964, Harry Bisel, MD, ASCO’s first President, recommended that “One full day … be held annually for scientific meetings.” The breadth and scope ASCO’s Annual Meeting now would have seemed unimaginable to the Society’s founders.
ASCO’s Founders Shared Vision for Future of Cancer Treatment (January 1, 2004): This article examines how Arnoldus Goudsmit, MD, PhD, and the rest of ASCO’s founders helped create a blueprint for the future of cancer care.
Exploring ASCO’s Roots (October 27, 2003): This article examines the founding principles of ASCO, as set forth in the Society’s first organizational meeting back in 1964.

SOURCE

http://www.asco.org/about-asco/society-history

Citigroup last year put a $35 billion figure on the market potential for these drugs, the oft-cited megablockbuster number helps explain why these companies are so interested in being among the first to the market.

Bristol-Myers Squibb (($BMY), Naomi Kresge and Robert Langreth report, is devoting an estimated $649 million to its immuno-oncology work, which is primarily devoted to getting nivolumab through the clinic and into the market.

Merck ($MRK), which is furiously at work on MK-3475 as many of the rest of its projects struggle, at one point recently described its immuno-oncology program as a pipeline unto itself. But the pharma giant is actually a distant second at this stage of the race, at least in terms of spending, with an estimated commitment of $327 million. Then

Roche ($RHHBY) – programs costing an estimated $189 million – hasn’t enjoyed as much attention for its PD-L1 program for MPDL3280A, but new data from a small study on bladder cancer looked promising and its Genentech unit is looking to make a splash in Chicago.

AstraZeneca ($AZN) bring up the rear, with $145 million on immuno-oncology – prospects with its immuno-oncology program for the PD-L1 therapy MEDI4736

Cancer vaccines were once the darlings of the R&D field for immunotherapies, but as Emily Mullin reports in FierceVaccines, a string of failures has seriously dimmed the prospects for the one-time leaders in the field. Still, some new biotechs are coming along. And as I reported in a separate story today, big players like J&J are looking to find some new ways to better apply some old, and failed, technologies.

SOURCE

From: FierceBiotech <editors@fiercebiotech.com>
Reply-To: <editors@fiercebiotech.com>
Date: Thu, 29 May 2014 16:50:54 +0000 (GMT)
To: <avivalev-ari@alum.berkeley.edu>
Subject: | 05.29.14 | ASCO: Top R&D bets crest $1B in immuno-oncology; J&J bags new prostate cancer tech

J&J expands prostate cancer program with cancer vax tech from Aduro

May 29, 2014 | By John Carroll

Johnson & Johnson’s ($JNJ) busy deal team in California has nailed down another development pact–this time zeroing in on new technology at a Berkeley biotech that will be used to expand its considerable efforts on prostate cancer R&D. And the deal includes rights to a failed cancer vaccine program which has recently sparked some positive trial results in a follow-up effort aimed at salvaging the work.

Aduro CEO Stephen Isaacs

This new deal from the J&J Innovation center zeroes in on a pact to license therapeutic candidates from Aduro BioTech’s drug development platform, which is focused on kicking up an immune response. The platform tech involves the use of live-attenuated double deleted Listeria monocytogenes strains to spawn the antigens needed to provoke an immune system attack on cancer.

Aduro didn’t break down the dollars in the deal, but the whole package of milestones and an upfront tallies up to $365 million, most of which is likely back ended.

SOURCE

J&J expands prostate cancer program with cancer vax tech from Aduro – FierceBiotech http://www.fiercebiotech.com/story/jj-expands-prostate-cancer-program-cancer-vax-tech-aduro/2014-05-29#ixzz3388xfcqU

Like Merck and AstraZeneca, Bristol-Myers is fascinated by the therapeutic potential of marrying an immune checkpoint drug with a therapy–INCB24360–that is designed to spur an immune system attack on cancer cells. Their Phase I/II study, which will explore the combos impact on multiple tumor types, is being co-funded by the two companies with Incyte taking the lead on the work.

“Given the encouraging data for Incyte’s IDO1 inhibitor and our current understanding of nivolumab’s anti-tumor immune response, we see this as an important area of study to add to our broad clinical development program,” said Bristol’s Michael Giordano in a statement.

CytomX, meanwhile, is gaining a $50 million upfront, unspecified preclinical development milestones and up to $298 million in additional milestones for each of up to 4 new “Probodies,” or new drug candidates. The targets include CTLA-4, a well-validated target in the field.

The biotech is a 2013 Fierce 15 company which was spun out from the labs of the University of California, Santa Barbara. Their next-level antibodies come with a peptide that blocks the antibody’s ability to bind to an antigen until it’s clipped off by a disease-associated enzyme.

– here’s the release on the Incyte deal
– see the release on the CytomX partnership

SOURCE
Bristol-Myers adds $1.24B deal plus a partnership in immuno-oncology deal frenzy – FierceBiotech http://www.fiercebiotech.com/story/bristol-myers-adds-348m-deal-plus-partnership-immuno-oncology-deal-frenzy/2014-05-27#ixzz3389rRiFZ

Bristol-Myers Squibb: It’s all about the ‘breakthrough’ drug nivolumab now

May 15, 2014 | By John Carroll

Bristol-Myers ($BMY) has one of the best drug development track records in the industry, and the big biotech is devoting major resources to its immuno-oncology lead. Bristol-Myers issued 5 new releases on nivolumab last night, and they all followed an early-morning statement on a new nivo combo study being mounted with Celldex.

The FDA helped make Bristol-Myers’ case for the PD-1 drug by giving nivolumab breakthrough status for Hodgkin’s lymphoma after failure of autologous stem cell transplant and brentuximab. But the analysts were hungry for more data, not bragging rights to a drug they had assigned blockbuster expectations to long ago.

They got a taste of that with promising results for nivolumab combined with Yervoy in previously treated renal cancer.

“In the Phase Ib CheckMate-016 trial, which evaluated the safety and tolerability of nivolumab at different doses and schedules as part of a regimen with other agents, (the overall response rate) for the investigational combination regimen of nivolumab and Yervoy (ipilimumab) ranged from 43-48% with a 24-week progression free survival rate that ranged from 64-65% in previously treated and treatment-naïve patients,” Bristol reported.

“These data are quite good, but perhaps not as ‘mind blowing’ as the combo data were in melanoma at last year’s ASCO,” says ISI’s Mark Schoenebaum.

Schoenebaum was more enthusiastic about nivo plus chemo in first-line lung cancer. “The one-year landmark (overall survival rates) in the abstract are stellar at 59%-87% (depending on chemo regimen and histology) which is above what you would expect historically (historical rates are 40%-50%).” But with serious signs of toxicity and a muted response among patients, expectations of Yervoy plus nivolumab in first-line lung cancer are plunging.

That’s the point that a lot of investors seized on Thursday morning, particularly after BMO Capital downgraded the stock after considerable speculation regarding the potential of Yervoy and nivo in lung cancer. Shares of Bristol-Myers slid 6% this morning.

There’s plenty more coming up on nivolumab at ASCO, so stay tuned.

– here’s the release from Bristol-Myers on the renal cell results
– here’s the release on lung cancer

SOURCE

Bristol-Myers Squibb: It’s all about the ‘breakthrough’ drug nivolumab now – FierceBiotech http://www.fiercebiotech.com/story/bristol-myers-squibb-its-all-about-breakthrough-drug-nivolumab-now/2014-05-15#ixzz338AGBggx

Read Full Post »

Two new possible Drug Targets for Triple Negative Breast Cancer: The genes, MLF2 (myeloid leukemia factor 2) and RPL39 (a ribosomal protein) have roles in Angiogenesis

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Nitric Oxide in Health and Disease on May 29, 2014| Leave a Comment »

Two new possible Drug Targets for Triple Negative Breast Cancer: The genes, MLF2 (myeloid leukemia factor 2) and RPL39 (a ribosomal protein) have roles in Angiogenesis

Reporter: Aviva Lev-Ari, PhD,RN

Cornell University Scientists discover two new possible drug targets for triple negative breast cancer

Thursday 29 May 2014 – 1am PST

The suppression of two genes reduce breast cancer tumor formation and metastasis by interfering with blood vessel formation and recruitment, report scientists from Houston Methodist and five other institutions in the Proceedings of the National Academy of Sciences (now online). The findings may help medical researchers identify effective drug targets for triple negative breast cancer, or TNBC.

The genes, MLF2 (myeloid leukemia factor 2) and RPL39 (a ribosomal protein), were found to most profoundly impact the production of nitric oxide synthase, which helps regulate blood vessel behavior and could be crucial to the recruitment of new blood vessels to growing tumors. These genes impact the spread of TNBC throughout the body, and have not so far been linked with breast cancer.

“We have found two unique genes that may affect the most lethal type of breast cancer” said principal investigator and Houston Methodist Cancer Center Director Jenny Chang, M.D., “Most importantly, by knowing how these genes function, we have drugs that can block nitric oxide signaling and will begin a clinical trial in the Cancer Center in the near future”

About 42,000 new cases of triple negative breast cancer (TNBC) are diagnosed in the United States each year, about 20 percent of all breast cancer diagnoses. Patients typically relapse within one to three years of being treated. TNBC is distinguished from other breast cancers in that it does not express the genes for estrogen receptor, progesterone receptor, and Her2/neu and is frequently harder to treat.

By suppressing close to five hundred TNBC-related genes, Chang’s group found interference was strongest with MLF2 and RPL39 in triple negative breast cancer model tissue. The scientists also learned that mutations in these genes in human patients were associated with worse survival in (human) triple negative breast cancer patients.

The researchers went a step further, determining which configurations of small inhibitory RNA (siRNA) were most efficient at shutting down MLF2 and RPL39 in breast cancer stem cell lines. siRNA molecules interfere with the cell’s ability to express genes and have proven to be effective drug tools for a wide variety of diseases, including some cancers.

In preliminary studies, the combination of siRNA and chemotherapy agent docetaxel significantly reducedtumor volume relative to chemotherapy alone and also appeared to prolong survival. Separate analyses showed suppression with siRNA appeared to yield fewer metastases to lung tissue.

Earlier this year, Chang, Weill Cornell Medical College Dean Laurie Glimcher, M.D., and colleagues reported to Nature another possible drug target for TNBC patients called XBP1, another gene previously unassociated with breast cancer.

“Together with our colleagues in Weill Cornell, we are launching clinical trials that affect these unique novel pathways that may cause TNBC to spread. These trials have potential to significantly impact this highly aggressive form of breast cancer.”

Chang has a secondary affiliation with Weill Cornell Medical College as a professor of medicine. Also contributing to the PNAS paper were Bhuvanesh Dave, Sergio Granados-Principal, Rui Zhu, Haifa Shen, Xuewu Liu, Mauro Ferrari, Ming Zhan, Stephen T.C. Wong, and Muthiah Kumaraswami (Houston Methodist), Stephen Benz (Five3 Genomics), Shahrooz Rabizadeh and Patrick Soon-Shiong (Chan Soon-Shiong Institute for Advanced Health), Ke-Da Yu and Zhimin Shao (Shanghai Cancer Center and Cancer Institute of Fudan University), Xiaoxian Li and Michael Gilcrease (University of Texas M.D. Anderson Cancer Center), and Vivek Mittal, Xi Chen, and Steven S. Gross (Weill Cornell Medical College). The work was funded by grants from the National Cancer Institute (R01 CA138197, U54 CA149196), Golfers against Cancer, the Breast Cancer Research Foundation, Causes for a Cure, Team Tiara, the Emily W. Herrman Cancer Research Laboratory, the U.S. Department of Defense Innovator Expansion Award (BC104158), the Susan G. Komen for the Cure (KG 081694), and Fundacion Alfonso Martin Escudero (SGP)

SOURCE

http://www.medicalnewstoday.com/releases/277410.php

Learn which HER2-positive breast cancer treatment may be right for you

http://www.her2treatment.com/?cid=per_DI_MBPTUA8059&c=MBPTUA8059&moc=MBPTUA8059&utm_source=google&utm_medium=cpc&utm_term=her2%20survival&utm_campaign=2012%20Perjeta.com%20HCP%20Content%20(Jun12)%20HER2Lander&gclid=CLaG0qWl0b4CFStk7AodfSQA3A

ipilimumab, a Drug that blocks CTLA-4 Freeing T cells to Attack Tumors @DM Anderson Cancer Center

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, FDA Regulatory Affairs, Human Immune System in Health and in Disease, Innovation in Immunology Diagnostics, Interviews with Scientific Leaders, Translational Science on May 28, 2014| Leave a Comment »

ipilimumab, a Drug that blocks CTLA-4 Freeing T cells to Attack Tumors @DM Anderson Cancer Center

Reporter: Aviva Lev-Ari, PhD, RN

Article ID #140: ipilimumab, a Drug that blocks CTLA-4 Freeing T cells to Attack Tumors @DM Anderson Cancer Center. Published on 5/28/2014

WordCloud Image Produced by Adam Tubman

The immune system connection

To understand the cause of the swift progression, the team conducted gene expression profiling and RNA sequence analysis comparing control tumors to myofibroblast-depleted tumors.

Genes associated with tumor immunity were suppressed and fewer T cells and B cells infiltrated the myofibroblast-depleted tumors. The proportion of regulatory T cells, which suppress immune response, increased. They found greater expression of the immune checkpoint CTLA-4, which shuts down immune response.

The researchers then set up a new experiment using ipilimumab, a drug developed by co-author Jim Allison, Ph.D., chair of Immunology, that blocks CTLA-4, freeing T cells to attack tumors.

Jim Allison, Ph.D.

Mice with depleted myofibroblasts who were treated with ipilimumab to stifle CTLA-4 had an average survival increase of 60% compared to untreated control mice and those with either depleted myofibroblasts or treated with ipilimumab alone.

These findings suggest that

ipilimumab might work for patients with low levels of fibrosis in their tumors, Kalluri noted.
Combining ipilimumab with a hedgehog inhibitor is likely to work better for those with high-fibrosis.

The Kalluri laboratory is exploring these issues.

Co-authors with Kalluri, Maitra and Allison are first author Berna Özdemir, M.D., Ph.D., Julienne Carstens, Ph.D., Xiaofeng Zheng, Ph.D., Hikaru Sugimoto, Ph.D., Christoph Kahlert, Ph.D., and Valerie LeBleu, Ph.D. of Cancer Biology; Tsvetelina Pentcheva-Hoang, Ph.D., Tyler Simpson, Ph.D., and Padmanee Sharma, M.D., Ph.D., of Immunology; Chia-Chin Wu, Ph.D., and Lynda Chin, M.D., of Genomic Medicine; Hanane Laklai, Ph.D., and Valerie Weaver, Ph.D., of University of California, San Francisco; Sergey Novitskiy, M.D., Ph.D., and Harold Moses, M.D., of Vanderbilt University School of Medicine, Nashville, Tenn.; Ana De jesus-Acosta, M.D., Johns Hopkins Hospital, Baltimore; and Pedram Heidari, M.D., and Umar Mahmood, M.D., Ph.D., of Massachusetts General Hospital, Boston.

Ozdemir, Sigumoto, LeBleu, and Kahlert also were affiliated with Beth Deaconess Medical Center and Harvard Medical School during this research.

Kalluri holds the Rebecca Meyer Brown and Joseph Mellinger Brown Chair in Basic Science Research at MD Anderson. Maitra holds the Sheikh Khalifa Bin Zayed Al Nahyan Distinguished University Chair in Cancer Research and Allison the Vivian L. Smith Distinguished Chair in Immunology.

This research was funded by grants from the National Cancer Institute of the National Institutes of Health (UO1 CA151925, CA113669, CA125550, CA155370 and CA163191, DK55001), the Cancer Prevention and Research Institute of Texas; MD Anderson’s Metastasis Research Center; the OncoSuisse M.D./Ph.D. Scholarship, the Swiss National Science Foundation Fellowship and a research fellowship from Deutsche Forschungsgemeinschaft.

SOURCE

http://www.mdanderson.org/newsroom/news-releases/2014/tissue-surrounding-cancer-cells-hinders-pancreatic-cancer.html?elq=99d9769b143a4d8fa5797a8dffe4ca67&elqCampaignId=11

Study results consistent with failed clinical trial

Kalluri and colleagues used genetically engineered mouse models that allowed depletion of tissue-repair cells called myofibroblasts in pancreatic cancer. Myofibroblasts compose a major portion of supportive tissue called stroma and also produce collagen, which serves as a scaffold for wound-healing and tissue regeneration. Up to 90 percent of a pancreas tumor can consist of fibrotic support tissue.

When the scientists depleted myofibroblast production in mice with either early or later-stage pancreatic ductal adenocarcinoma their tumors became much more invasive, aggressive and lethal.

“We did these experiments thinking that we would show the importance of myofibroblasts and fibrosis in pancreas cancer progression, but the results went completely against that hypothesis,” Kalluri said.

Since myofibroblasts and collagen are thought to block chemotherapy, the team treated their myofibroblast-depleted mice with gemcitabine, the standard treatment for pancreas cancer. The drug did not have any effect on the disease course or improve survival.

These results track those of a major clinical trial that combined a myofibroblast-depleting drug called a hedgehog inhibitor with gemcitabine to treat pancreatic cancer patients. The trial was stopped in 2012 when an interim analysis showed the patients taking the combination had faster disease progression than the control group that took only gemcitabine, a surprising result.

“This paradigm-shifting study identifies the reason why the hedgehog-inhibitor trials failed,” said co-author Anirban Maitra, M.D., professor of Pathology and scientific director of the Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research.

Anirban Maitra, M.D.

All solid tumors include some degree of fibrosis, Maitra said, but not as much as pancreas cancer.

The team’s analysis of pancreatic tumors from 53 patients showed low levels of tumor myofibroblasts are associated with decreased survival.

Study findings are consistent with pathologic evidence that tumors with more fibrotic tissue more closely resemble normal pancreas tissue, indicating a better prognosis for patients, even though lab experiments indicated those tumors should be more aggressive, Maitra said.

“These findings also are likely to account for rather modest results in a phase I clinical trial of immunotherapy alone for pancreas cancer,” Maitra said. “But it’s not just a negative study, because it suggests what might work for these patients.”

And what might work hinges on immune checkpoint blockade.

SOURCE

http://www.mdanderson.org/newsroom/news-releases/2014/tissue-surrounding-cancer-cells-hinders-pancreatic-cancer.html?elq=99d9769b143a4d8fa5797a8dffe4ca67&elqCampaignId=11

Supportive tumor tissue surrounding cancer cells hinders, rather than helps, pancreatic cancer

Study shows fibrosis summons an immune attack, challenges theory that it blocks chemotherapy

MD Anderson News Release 05/22/14

Fibrous tissue long suspected of making pancreatic cancer worse actually supports an immune attack that slows tumor progression but cannot overcome it, scientists at The University of Texas MD Anderson Cancer Center report in the journal Cancer Cell.

“This supportive tissue that’s abundant in pancreatic cancer tumors is not a traitor as we thought but rather an ally that is fighting to the end. It’s a losing battle with cancer cells, but progression is much faster without their constant resistance,” said study senior author Raghu Kalluri, Ph.D., M.D., chair of Cancer

Raghu Kalluri, Ph.D., M.D.

Biology. “It’s like having a car with weak yet functioning brakes vs. having one with no brakes.”

The team’s findings point to a potential new avenue for guiding treatment, including immunotherapy, and offer an explanation for the failure of a promising combination drug approach in clinical trials.

“Cancer is one form of tissue injury. When our defense system detects damaged cells it sends soldiers to contain and repair the damage,” Kalluri said. “When it cannot remove the damaged cells and repair the injured area, our defensive fibrotic response tries to put a boundary around it, to contain it and prevent it from spreading.”

Pancreas cancer is resistant to treatment and only about 7 percent of patients survive for five years. An estimated 46,420 new U.S. cases will be diagnosed in 2014 and 39,590 people will die of the disease.

SOURCE

http://www.mdanderson.org/newsroom/news-releases/2014/tissue-surrounding-cancer-cells-hinders-pancreatic-cancer.html?elq=99d9769b143a4d8fa5797a8dffe4ca67&elqCampaignId=11

Read Full Post »

EmergingMed has guided more than 170,000 patients through a search for Cancer Clinical Trials

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Population Health Management, Genetics & Pharmaceutical, Regulated Clinical Trials: Design, Methods, Components and IRB related issues on May 28, 2014| Leave a Comment »

EmergingMed has guided more than 170,000 patients through a search for Cancer Clinical Trials

Reporter: Aviva Lev-Ari, PhD, RN

“We need to explain to the American public that the drugs we are benefiting from today did not come out of thin air,” says Armin Weinberg, director of Baylor College of Medicine’s Chronic Disease Prevention and Control Research Center in Houston. “Their participation in trials is the thing that is going to help us advance in all these battles against cancer, asthma, diabetes and hypertension.”

SOURCE

Matchmakers: Patients Meet Clinical Trials

http://online.wsj.com/news/articles/SB121071901838189901

Since December 2000, EmergingMed has guided more than 170,000 patients through a search for cancer clinical trials. (see WSJ coverage, press release)

EmergingMed’s Navigator service enables you to create a detailed profile to see if you match the eligibility requirements of more than 10,000 trials in the United States and Canada.

Our Clinical Trial Specialists will work with you by telephone to make sure you get the information you need to make important decisions about clinical trial options.

Cancer clinical trials are research studies that test how well new medical approaches work in people with early stage or advanced cancers. Each study answers scientific questions and tries to find better ways to prevent, screen for, diagnose, or treat a disease.

There are more than 250 types of cancer. Every cancer treatment—and every clinical trial—is designed for a very specific type and stage of cancer.

Video: The Cure for Cancer: Why Clinical Trials are Imperative

We suggest that you search for cancer clinical trials every time you review your treatment options. Why? Because studies only enroll patients at very specific times:

Just before a biopsy (to study tissue from a tumor)
Just before the first surgery or radiation treatment (neo-adjuvant studies)
Just after surgery or radiation treatment (adjuvant studies)
Soon after a cancer has recurred or spread (metastasized)
Soon after you learn that your cancer is spreading despite current treatment

Step 1: Create a profile online or by phone to find clinical trials that match your specific cancer diagnosis, stage and treatment history.

Step 2: Match your profile to the eligibility criteria of all the cancer clinical trials in our database.

Step 3: Navigation support from our Clinical Trial Specialists will help you connect with the doctors and nurses conducting the trials you match, answer questions during your search, and help you quickly gather information to share with your doctor.

Search Online

Cancer Prevention and Early Detection

Cancer Treatment – Adults
Cancer Treatment – Children and Patients under 18

Select a Diagnosis

Cancer Prevention and Early Detection Trials for Men
Cancer Prevention and Early Detection Trials for Women

We’ve all heard of them, but what exactly are clinical trials?

Put simply, a clinical trial is a scientific study of how a new medicine or treatment works in people. Through clinical studies, doctors find new and better ways to prevent, detect, diagnose, control, and treat illnesses.

People who participate in clinical trials are not guinea pigs. A therapy reaches the point where it can be evaluated in a clinical trial only after it proves successful in animals and the laboratory. The researchers who run the trials are actively trying to offer the participants the best available treatment that will be successful against their disease.

New medicines and treatments that are helpful and safe in test tubes and in animals must also prove safe and effective in humans before doctors can prescribe them. This testing in humans is permitted only if a person volunteers to participate and understands the risks and benefits of taking part in a study. This informed consent to participate must be based on a patient volunteer’s understanding of what is involved in the study, including potential risks and benefits. Volunteers may leave a study at any time.

Types of clinical trials
Clinical trial phases
Inclusion/exclusion criteria
The initial screening visit
Informed consent
Getting paid to participate in clinical trials
Where to go for more information

Types of clinical trials Top
There are several types of trials, according to the National Institutes of Health:

Treatment trials test new therapies that may increase the life expectancy or reduce suffering in people who have a serious illness.
Prevention trials test new approaches, such as medicines, vaccines, vitamins, minerals, or other supplements that doctors believe may lower the risk of a certain disease.
Screening/early detection trials test the best way to find a disease, especially in its early stages.
Quality of Life trials (also called Supportive Care trials) explore ways to improve comfort and quality of life for patients with a disease.
Genetics trials are meant to improve the ability to look for an inherited risk of illness.

Clinical Trial Phases Top
Testing of a new therapy (i.e., treatment trials) progresses in an orderly series of steps, called phases. This allows researchers to ask and answer questions in a way that results in reliable information about the drug and protects the patients. Clinical trials are usually classified into one of four phases by the U.S. Food and Drug Administration, which oversees the approval process:

Phase I trials: These first studies in people evaluate how a new drug should be given (by mouth, injected into the blood, or injected into the muscle,) how often, and what dose is safe. In particular, these studies are also looking for the highest dose that can safely be given with the fewest serious side effects (maximum tolerated dose). In addition, a Phase I trial might evaluate a new combination of 2 drugs where one or both of the drugs, alone, might be well known but doctors have never before studied the two together. In these combination studies, doctors are watching closely for potential interactions and new side effects when the two drugs are given together.

By the time a new treatment reaches the phase I level, it has proved beneficial in several animal models and in the laboratory. A Phase I trial usually enrolls only a small number of patients, sometimes as few as a dozen, and is offered only at major cancer centers. It is important to realize that there is no chance that a patient will receive a placebo in a Phase I clinical trial. Patients enrolling in Phase I trials are the first to help doctors identify promising new drugs and the scientific knowledge that will ultimately help future patients.

Phase I trials usually enroll patients with advanced disease for whom no standard therapies are available. Patients considering Phase I trials should have a reasonable expectation that the new drugs (or drug combinations) might shrink their tumors or reduce their tumor burden. However the risks associated with being one of the first people to try a new drug-or a new drug combination-should be weighed very carefully since the side effects of the new drug/combination will not be well understood at the beginning of a Phase I study.
Phase II trials: A phase II trial continues to test the safety of the drug, and begins to evaluate how well the new drug works. Phase II studies usually focus on a particular aspect of a disease. Like phase I trials, these trials do not test the difference between two therapies, so the participants will almost always get the experimental treatment. There is still no chance that a participant in the trial will receive a placebo.
Phase III trials: These studies test a new drug, a new combination of drugs, or a new surgical procedure in comparison to the current standard for treatment. A participant will usually be assigned to the standard treatment group or the new treatment group at random (called randomization). Phase III trials often enroll large numbers of people and may be conducted at many doctors’ offices, clinics, and disease centers nationwide.

In phase III trials, patients rarely receive a placebo – in fact, only when there is no standard therapy for the disease. Otherwise, people who participate in phase III clinical trials will either receive the best available standard therapy or the experimental therapy, with an equal chance of receiving either treatment.
Phase IV trials: These are often required when a drug manufacturer wishes to test an already approved therapy for a different medical condition or in a different formulation than it was originally approved for. The manufacturer is not allowed to make new claims about their product until it is properly tested. It is possible (though unlikely) that a placebo may be used in the control group in a phase IV trial.

Inclusion/exclusion criteria Top
When designing a clinical research study, an investigator must first decide who should be in the study and who should be excluded. Unless the researchers are very firm and diligent about sticking to those inclusion/exclusion criteria, the entire study can be weakened. The researchers must therefore try and find a balance between identifying those people who are most appropriate to test a new therapy and casting a wide enough net to ensure that they will have enough participants to make the results statistically significant.

Inclusion/exclusion criteria might be such factors as the age of the participants – many studies will only include people over 18 years old, for example – the date of diagnosis of the illness, other therapies, and other illnesses that the participant might have. Other inclusion/exclusion criteria might be the stage of the illness – many studies try and exclude patients who have very advanced illnesses – how active the participants are in their day-to-day routines, and the ability to take oral medications.

Inclusion/exclusion criteria should be explained to each potential participant in a clinical research trial before they are enrolled in the study.

The initial screening visit Top
After a person has decided to participate in a clinical study, they will be scheduled by the study coordinator for a preliminary screening visit. During that visit, the inclusion/exclusion criteria will be detailed for the participant. The study coordinator will also explain the study, the procedures that need to be followed and answer any questions that may arise. This process is called informed consent and is essential before any volunteer is enrolled in any clinical trial. More on the concept of informed consent can be found below

The initial screening visit is also an opportunity for the study coordinator to obtain a full medical history from the participant. He or she will also usually perform a physical exam and schedule any laboratory tests that may be necessary before participation in the study can begin.

Informed consent Top
The United States government is very strict about the guidelines of medical research performed on people. An Institutional Review Board (IRB) approves and monitors every clinical trial performed in the US to minimize the risks to the study participants and to make sure that the potential benefits of the new therapy outweigh those risks. An IRB is usually made up of physicians, experts in biomedical ethics, statisticians, and members of the community and its sole charge is to make certain that clinical research adheres to the strictest ethical guidelines.

Every participant in a clinical trial in the United States has the right to informed consent. In fact, nobody should even consider joining a trial without access to key information that must be provided by the investigators in easy-to-understand language.

This information (adapted from the NIH) includes:

why the research is being done
what the researchers are hoping to accomplish
what the different therapies being tested are and how they are thought to work
any risks associated with the therapies
the potential benefits for the participant
other available treatments (with a discussion of their efficacy and side effects)
the fact that participants may leave the study at any time

Getting paid to participate in clinical trials Top
Some clinical trials will pay people for participating in the research but they are rare, primarily because the National Institutes of Health wish to discourage patients from participating in clinical trials solely for financial purposes.

Most clinical trial sponsors, however, will reimburse participants for reasonable travel and food expenses accumulated while they are in the trial. The article below describes specific legislation meant to ensure that people who participate in clinical research are not harmed financially by their involvement.

Where to go for more information Top
The National Institutes of Health have a very comprehensive website that deals exclusively with clinical trials and the issues described above. It can be found at www.clinicaltrials.gov.

Modified: May 2014

SOURCE

http://www.emergingmed.com/pub_AboutClinicalTrials.asp

Read Full Post »

Cancer Labs at School of Medicine @ Technion: Janet and David Polak Cancer and Vascular Biology Research Center

Posted in Academic Publishing, Autologous Cell Therapy, Bio Instrumentation in Experimental Life Sciences Research, BioBanking, Biological Networks, Gene Regulation and Evolution, Biomarkers & Medical Diagnostics, Biomedical Measurement Science, BioSimilars, CANCER BIOLOGY & Innovations in Cancer Therapy, Cardiac muscle regeneration, Cardiovascular Pharmacogenomics, Cell Biology, Signaling & Cell Circuits, Chemical Biology and its relations to Metabolic Disease, Chemical Genetics, Circulating Progenitor Cells, Computational Biology/Systems and Bioinformatics, Cytoskeleton, Diagnostic Immunology, Drug Delivery Platform Technology, Drug Toxicity, Frontiers in Cardiology and Cardiovascular Disorders, Genome Biology, Genomic Testing: Methodology for Diagnosis, Human Immune System in Health and in Disease, Immunodiagnostics, Innovation in Immunology Diagnostics, Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough, Interviews with Scientific Leaders, Personalized and Precision Medicine & Genomic Research, Pharmaceutical Analytics, Pharmaceutical R&D Investment, Pharmacogenomics, Pharmacologic toxicities, Population Health Management, Genetics & Pharmaceutical, Proteomics, Regenerative Biology and Medicine, Regulated Clinical Trials: Design, Methods, Components and IRB related issues, Scientist: Career considerations, Signaling, Stem Cells for Regenerative Medicine, Technology Transfer: Biotech and Pharmaceutical, Translational Science, Ubiquitinylation on May 28, 2014| Leave a Comment »

Cancer Labs at School of Medicine @ Technion

Reporter: Aviva Lev-Ari, PhD, RN

Article ID #139: Cancer Labs at School of Medicine @ Technion: Janet and David Polak Cancer and Vascular Biology Research Center. Published on 5/28/2014

WordCloud Image Produced by Adam Tubman

Janet and David Polak Cancer and Vascular Biology Research Center. The Rappaport Faculty of Medicine Research Institute and Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

The center was established in 2003 to promote an in-depth interdisciplinary basic and clinical research on the control of cellular and molecular processes that are involved in cancer initiation and progression. We strongly believe that the understanding of basic biological processes that underlie normal development and their deregulation in cancer, is crucial for our ability to identify molecular targets for early detection, intervention, and cure of the disease. We are interested in a broad view of cancer – from the single malignantly transformed cell and its microenvironment, through the entire tumor in the animal. We focus on targeted ubiquitin-mediated degradation of key regulatory proteins that are involved in malignant transformation [Prof. Aaron Ciechanover (Nobel Prize in Chemistry 2004)], angiogenesis and cancer progression (Prof. Gera Neufeld), metastasis and tumor microenvironment (Prof. Israel Vlodavsky), as well as genetic and genomic dissection of embryonic and cancer transcriptional networks (Dr. Amir Orian). Towards these objectives, we combine molecular, biochemical, cell biological with Drosophila genetic and genomics experimental approaches, as well as employing advanced models of angiogenesis and metastasis.

We believe that scientific excellence and collegiality go together. Therefore, the center has an open and friendly atmosphere, creating a highly stimulating environment. The center is located in the 11th Floor of the Rappaport Faculty of Medicine building. It currently trains 45 graduate students, post-doctoral fellows, clinicians and researchers that are at the heart of our research. Formal and informal collaborations between individuals and laboratories are on-going and encouraged. We are running a series of joint seminars to which we invite researchers from Israel and abroad. The Center has advanced state-of-the-art microscopic and image analysis equipment, as well as other shared pieces of infrastructural equipment . The center is an integral part of the Faculty of Medicine and the Rappaport Research Institute which are home for excellent research groups, and enjoys their advanced Interdepartmental Equipment Unit. It is also adjacent to the Rambam Medical Center – the major hospital in the north of Israel – which provides us with access to rich clinical material and collaboration with clinicians. Many of them spend active research periods in our laboratories and bring the bench closer to the patient bed and vice versa. The Center is in an active phase of growth, and offers excellent research opportunities, space and facilities for students, post-doctoral fellows, and physicians.

Research Groups

The Ubiquitin System and Cellular Protein Turnover and Interactions	Immunity and Host Defense
Cardiovascular Biology	The Central Nervous System in Health and Disease
Developmental Biology and Cancer Research	Genetics

SOURCE

http://www.rappaport.org.il/Rappaport/Templates/ShowPage.asp?DBID=1&TMID=842&FID=76

The cancer and vascular biology research center was established in 2003 to promote an in-depth interdisciplinary basic and clinical research on the control of cellular and molecular processes that are involved in cancer development and progression. Our goal is to advance knowledge in fundamental biological questions that are highly relevant for cancer.


	The cancer and vascular biology research center was established in 2003 to promote an in-depth interdisciplinary basic and clinical research on the control of cellular and molecular processes that are involved in cancer development and progression. Our goal is to advance knowledge in fundamental biological questions that are highly relevant for cancer.

SOURCE

http://www.technioncancer.co.il/index.php

Home >> Research Groups

Aaron Ciechanover
Protein Turnover

Intracellular protein degradation and mechanisms of cancer

Israel Vlodavsky
Cancer Biology

Impact of heparanase and the tumor microenvironment on cancer progression: Basic aspects and clinical implications

Gera Neufeld
Tumor Progression & Angiogenesis

Blood vessels and tumor progression: The neuropilin connection

Amir Orian
Genetic Networks

Genetic networks in development and cancer

Home
About the Cancer Centers
Research Groups
Administration / Contact
Join – Us

Seminars and Events
Links
Beyond Science
Friends and supporters

Ms. Sigal Alfasi – Izrael, Center’s coordinator
e-mail: gsigal@tx.technion.ac.il
Tel: +972-4-829-5424
Fax: +972-4-852-3947

SOURCE

http://www.technioncancer.co.il/ResearchGroups.php

Yuval Shaked, PhD

Publications by Yuval Shaked, PhD

Assistant Professor of Molecular Pharmacology
PhD, 2004 – Hebrew University, Israel

Understanding host – tumor interactions during cancer therapy

Personalized medicine holds promise of better cures with fewer side effects for many diseases. Individualized cancer therapy is sometimes utilized after multiple attempts of standard therapies and is based on several considerations, such as tumor type, acquired resistance to a specific therapy, previous treatment protocols, and other tumor-related factors. We have recently demonstrated that many cancer therapies can induce pro-tumorigenic or metastatic effects that derive not only from the tumor cells themselves, but also from host cells within the tumor microenvironment. The focus of research in my laboratory is to identify, characterize, and seek ways to block such pro-tumorigenic host effects observed after anti-cancer therapy, and thus potentially improve the outcome of current cancer therapies. Our findings may foster a paradigm shift in cancer therapy by minimizing the gap between preclinical findings and the clinical setting, laying the foundation for development of entirely new strategies for improving cancer therapy.

SOURCE

http://www.rappaport.org.il/Rappaport/Templates/ShowPage.asp?DBID=1&TMID=610&FID=77&PID=0&IID=1268

Levels of Tumor-associated Gene Expression & Cancer Biomarkers: OncoCyte’s PanC-Dx Diagnostic Tests of Cornell Medical College Blood Samples derived from Healthy and Lung Cancer Patients

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Genome Biology, Hematology, Personalized and Precision Medicine & Genomic Research on May 27, 2014| Leave a Comment »

Levels of Tumor-associated Gene Expression & Cancer Biomarkers: OncoCyte’s PanC-Dx Diagnostic Tests of Cornell Medical College Blood Samples derived from Healthy and Lung Cancer Patients

Reporter: Aviva Lev-Ari, PhD, RN

OncoCyte, Cornell Collaborate on Lung Cancer Dx

May 27, 2014

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb) – BioTime subsidiary OncoCyte has entered into a deal with Cornell University to collaborate on developing a lung cancer diagnostic test, the parties announced today.

As part of the deal, Weill Cornell Medical College will provide blood samples derived from healthy patients and lung cancer patients. OncoCyte researchers will then use the firm’s PanC-Dx diagnostic tests to analyze the samples to determine levels of tumor-associated gene expression, including levels of the company’s proprietary PanC-Dx cancer biomarkers.

A data set from more than 700 patients will be produced that combines the results of the analyses with results from a clinical study being conducted by OncoCyte’s collaborators at the Wistar Institute. Those two entities announced a collaboration in the fall to develop a lung cancer diagnostic test.

Using the data, OncoCyte will evaluate potential cancer markers in order to develop a multimarker test for detecting lung cancer. OncoCyte retains all rights to develop and market its proprietary lung cancer diagnostic products under the terms of the deal, the partners said. Further financial and other terms were not disclosed.

PanC-Dx is a class of non-invasive diagnostic tests based on a set of cancer markers characterized by gene expression patterns in several cancer types. How the marker panel performs in determining disease progression in various categories of patients “will determine the specific nature of the test to be developed and the approval pathway that OncoCyte will pursue,” the partners said.

They noted that the US Preventative Services Task Force recently recommended that certain high-risk patients undergo annual screenings for lung cancer. The task force suggested screening using low-dose computed tomography, a technology that while sensitive in detecting early stage lung cancer in large clinical studies also has a high false-positive rate of about 25 percent.

OncoCyte CEO Joseph Wagner said in a statement that the high number of false-positive results could result in more than $1 billion annually in unnecessary healthcare costs in the US. “Physicians, payers, and patients would therefore welcome a simple to use, low-cost, blood-based test that can help guide patient management decisions by non-invasively ruling out the presence of cancer,” he said.

Asymptomatic Patients After Percutaneous Coronary Intervention: Low Yield of Stress Imaging – Population-Based Study

Posted in Cardiac and Cardiovascular Surgical Procedures, Frontiers in Cardiology and Cardiovascular Disorders, Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound, PCI, Stents & Tools on May 27, 2014| Leave a Comment »

Asymptomatic Patients After Percutaneous Coronary Intervention: Low Yield of Stress Imaging – Population-Based Study

Reporter: Aviva Lev-Ari, PhD, RN

Low Yield of Stress Imaging in a Population-Based Study of Asymptomatic Patients After Percutaneous Coronary Intervention

+Author Affiliations

From the Division of Cardiovascular Medicine, Department of Internal Medicine (T.P., J.W.A., M.B., R.J.G.) and Department of Health Sciences Research (D.C., D.H.), Mayo Clinic, Rochester, MN.

Correspondence to Raymond J. Gibbons, MD, Division of Cardiovascular Diseases, Mayo Clinic, 200 1st St SW, Rochester, MN 55905-0001. E-mail gibbons.raymond@mayo.edu

Abstract

Background—Little is known about the clinical value of stress imaging studies in asymptomatic patients after percutaneous coronary intervention (PCI).

Methods and Results—Residents of Olmsted County, MN, who underwent PCI were followed up for the occurrence of stress imaging (stress nuclear or stress echocardiography), coronary angiography, or coronary artery bypass grafting (without angiography) as initial procedures after PCI. Patients whose first follow-up procedure was a stress imaging test were evaluated for their symptom status at the time of the study and whether they underwent angiography or revascularization (PCI or coronary artery bypass grafting) within 90 days. Of 1848 patients who underwent PCI during the study period, 710 (38%) had stress imaging as their initial procedure after PCI, and 241 (13% of the entire cohort) were asymptomatic at the time of testing. The majority (86%) of these 241 patients underwent PCI for acute myocardial infarction or unstable angina. Within 90 days of stress imaging, 16 of the 241 asymptomatic patients underwent angiography, and 2 patients were revascularized. Stratified by timing after PCI, none of 138 asymptomatic patients tested within 2 years of PCI underwent revascularization. Two of 103 asymptomatic patients tested after 2 years from PCI underwent revascularization. Compared with patients who were asymptomatic at the time of stress imaging, patients who did not undergo any follow-up procedures (stress imaging, angiography, or coronary artery bypass grafting) after the index PCI were older, were more likely to have comorbidities, and had significantly greater all-cause mortality (P<0.001).

Conclusions—In a population-based sample of patients undergoing PCI primarily for acute coronary syndromes, 1 in 8 had subsequent stress imaging when they were asymptomatic. These stress imaging tests resulted in further revascularization in <1% of patients. The low rate of downstream revascularization suggests that stress imaging in asymptomatic patients after PCI has low value.

Key Words:

Received June 23, 2013.
Accepted January 30, 2014.

Read Full Post »

Immunity and Host Defense – A Bibliography of Research @Technion

Posted in Biological Networks, Gene Regulation and Evolution, Biomarkers & Medical Diagnostics, Biomedical Measurement Science, CANCER BIOLOGY & Innovations in Cancer Therapy, Cancer Prevention: Research & Programs, Cell Biology, Signaling & Cell Circuits, Chemical Biology and its relations to Metabolic Disease, Chemical Genetics, Diagnostic Immunology, Drug Delivery Platform Technology, Drug Toxicity, FDA Regulatory Affairs, Genome Biology, Genomic Testing: Methodology for Diagnosis, Human Immune System in Health and in Disease, Immunodiagnostics, Innovation in Immunology Diagnostics, Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough, Interviews with Scientific Leaders, Medical and Population Genetics, Molecular Genetics & Pharmaceutical, Personalized and Precision Medicine & Genomic Research, Pharmaceutical Analytics, Pharmaceutical R&D Investment, Pharmacogenomics, Pharmacologic toxicities, Population Health Management, Genetics & Pharmaceutical, Proteomics, Regulated Clinical Trials: Design, Methods, Components and IRB related issues, Scientist: Career considerations, Signaling, Technology Transfer: Biotech and Pharmaceutical, Translational Science on May 27, 2014| Leave a Comment »

Immunity and Host Defense – A Bibliography of Research @Technion

Reporter: Aviva Lev-Ari, PhD, RN

Article ID #138: Immunity and Host Defense – A Bibliography of Research @Technion. Published on 5/27/2014

WordCloud Image Produced by Adam Tubman

Antigen-Dependent Integration of Opposing Proximal TCR-Signaling Cascades Determines the Functional Fate of T Lymphocytes

2014

Shai Shen-Orr, PhD
Authors : Wolchinsky R, Hod-Marco M, Oved K, Shen-Orr SS, Bendall SC, Nolan GP, Reiter Y.

J Immunol. 2014 Mar 1;192(5):2109-19.

Identification of functionally important conserved trans-membrane residues of bacterial P(IB) -type ATPases

2013

Oded Lewinson, PhD
Authors : Zhitnitsky D, Lewinson O.

Mol Microbiol. 2013 Dec 19. doi: 10.1111/mmi.12495. [Epub ahead of print] PubMed PMID: 24350798.

Variability in the immune system: of vaccine responses and immune states

2013

Shai Shen-Orr, PhD
Authors : Shen-Orr SS, Furman D.

Curr Opin Immunol. 2013 Aug;25(4):542-7.

Computational deconvolution: extracting cell type-specific information from heterogeneous samples.

2013

Shai Shen-Orr, PhD
Authors : Shen-Orr SS, Gaujoux R.

Curr Opin Immunol. 2013 Oct 19. [Epub ahead of print] PubMed PMID: 24148234.

Challenges and promise for the development of human immune monitoring.

2013

Shai Shen-Orr, PhD
Authors : Shen-Orr S.

Rambam Maimonides Med J. 2012 Oct 31;3(4):e0023.

Homeostatic regulation of aging and rejuvenation in the B lineage cells

2013

Doron Melamed, PhD
Authors : Melamed D.

Crit Rev Immunol. 2013;33(1):41-56.

Variability in the immune system: of vaccine responses and immune states

2013

Shai Shen-Orr, PhD
Authors : Shen-Orr S, Furman D.

Curr Opin Immunol. 2013 Aug 13. doi:pii: S0952-7915(13)00113-1.

A single intact ATPase site of the ABC transporter BtuCD drives 5% transport activity yet supports full in-vivo vitamin B12 utilization.

2013

Oded Lewinson, PhD
Authors : Tal N, Ovcharenko E, Lewinson O.

Proc Natl Acad Sci U S A. (March 19 Epub ahead of print)

Apoptosis and other immune biomarkers predict influenza vaccine responsiveness.

2013

Shai Shen-Orr, PhD
Authors : Furman D, Jojic V, Kidd B, Shen-Orr S, Price J, Jarrell J, Tse T, Huang H, Lund P, Maecker HT, Utz PJ, Dekker CL, Koller D, Davis MM.

Molecular Systems Biology. 9, 659

The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications.

2013

Nathan Karin, PhD
Authors : Shachar, I., and N. Karin.

J Leukoc Biol 93:51-61.

Two molybdate/tungstate ABC transporters that interact very differently with their substrate binding proteins.

2013

Oded Lewinson, PhD
Authors : Vigonsky, Ovcharenko E, Lewinson O.

Proc Natl Acad Sci U S A. (March 19 Epub ahead of print)

Dissecting the Autocrine and Paracrine Roles of the CCR2-CCL2 Axis in Tumor Survival and Angiogenesis.

2012

Nathan Karin, PhD
Authors : Izhak, L., G. Wildbaum, S. Jung, A. Stein, Y. Shaked, and N. Karin.

PloS one 7:e28305

Dose-related effects of hyperoxia on the lung inflammatory response in septic rats

2012

Nitza Lahat, PhD
Authors : Waisman D, Brod V, Rahat MA, Amit-Cohen BC, Lahat N, Rimar D, Menn-Josephy H, David M, Lavon O, Cavari Y, Bitterman H.

Shock. 2012 Jan;37(1):95-102.

Robust and sensitive analysis of xMap bead arrays using SAxCyB.

2012

Shai Shen-Orr, PhD
Authors : Won JH, Goldberger O, Shen-Orr SS, David MM, Olshen RA.

Proc Natl Acad Sci U S A. 109, 2848-53.

The Entamoeba histolytica methylated LINE-binding protein EhMLBP provides protection against heat shock

2012

Serge Ankri, PhD
Authors : Katz S, Kushnir O, Tovy A, Siman Tov R, Ankri S.

Cell Microbiol. 2012 Jan;14(1):58-70

Hypoxia increases membranal and secreted HLA-DR in endothelial cells, rendering them T-cell activators.

2011

Nitza Lahat, PhD
Authors : Lahat N, Bitterman H, Weiss-Cerem L, Rahat MA.

Transpl Int. 2011 Oct;24(10):1018-26.

The Entamoeba histolytica methylated LINE-binding protein EhMLBP provides protection against heat shock.

2011

Serge Ankri, PhD
Authors : Katz S, Kushnir O, Tovy A, Siman Tov R, Ankri S.

Cell Microbiol. 2011 Sep 8. [Epub ahead of print]

Dose-Related Effects of Hyperoxia on the Lung Inflammatory Response in Septic Rats. Shoc

2011

Nitza Lahat, PhD
Authors : Waisman D, Brod V, Rahat MA, Amit-Cohen BC, Lahat N, Rimar D, Menn-Josephy H, David M, Lavon O, Cavari Y, Bitterman H.

2011 Sep 3. [Epub ahead of print]

Glucose starvation boosts Entamoeba histolytica virulence.

2011

Serge Ankri, PhD
Authors : Tovy A, Hertz R, Siman-Tov R, Syan S, Faust D, Guillen N, Ankri S.

PLoS Negl Trop Dis. 2011 Aug;5(8):e1247.

The binding activity of Mel-18 at the Il17a promoter is regulated by the integrated signals of the TCR and polarizing cytokines.

2011

Eur J Immunol. 2011 Aug;41(8):2424-35.

phosphorylation of SLP-76 at tyrosine 173 is required for activation of T and mast cells.

2011

Deborah Yablonski, PhD
Authors : Sela M, Bogin Y, Beach D, Oellerich T, Lehne J, Smith-Garvin JE, Okumura M, Starosvetsky E, Kosoff R, Libman E, Koretzky G, Kambayashi T, Urlaub H, Wienands J, Chernoff J, Yablonski D. Sequential

EMBO J. 2011 Jul 1;30(15):3160-72.

The binding activity of Mel-18 at the Il17a promoter is regulated by the integrated signals of the TCR and polarizing cytokines.

2011

Orly Avni, PhD
Authors : Hod-Dvorai R, Jacob E, Boyko Y, Avni O.

Eur J Immunol. 2011 Jun 15. [Epub ahead of print]

MMP expression in leaking filtering blebs and tears after glaucoma filtering surgery.

2011

Nitza Lahat, PhD
Authors : Mathalone N, Marmor S, Rahat MA, Lahat N, Oron Y, Geyer O.

Graefes Arch Clin Exp Ophthalmol. 2011 Mar 31. [Epub ahead of print]

B cell depletion reactivates B lymphopoiesis in the BM and rejuvenates the B lineage in aging.

2011

Doron Melamed, PhD
Authors : Keren Z, Naor S, Nussbaum S Golan K, Itkin T, Sasaki Y, Schmidt-Supprian M, Lapidot T, Melamed D.

Blood 117, 3104 – 3112.

Chronic B cell deficiency from birth prevents age-related alterations in the B lineage J.

2011

Doron Melamed, PhD
Authors : Keren Z, Averbuch D, Shahaf G, Zisman-Rozen S, Golan K, Itkin T, Lapidot T, Mehr R, Melamed D.

Immunol 187, 2140 – 2147.

Epigenetics in the unicellular parasite Entamoeba histolytica.

2010

Serge Ankri, PhD
Authors : Tovy A, Ankri S.

Future Microbiol. 2010 Dec;5:1875-84.

The MAPK/ERK and PI3K pathways additively coordinate the transcription of recombination-activating genes in B lineage cells

2010

Orly Avni, PhD
Authors : Novak R, Jacob E, Haimovich J, Avni O, Melamed D.

J Immunol. 2010 Sep 15;185(6):3239-47

A fusion protein encoding the second extracellular domain of CCR5 arrests chemokine-induced cosignaling and effectively suppresses ongoing experimental autoimmune encephalomyelitis

2010

Nathan Karin, PhD
Authors : Sapir Y, Vitenshtein A, Barsheshet Y, Zohar Y, Wildbaum G, Karin N.

J Immunol. 2010 Aug 15;185(4):2589-99.

Antigen-specific CD25- Foxp3- IFN-gamma(high) CD4+ T cells restrain the development of experimental allergic encephalomyelitis by suppressing Th17

2010

Nathan Karin, PhD
Authors : Wildbaum G, Zohar Y, Karin N.

Am J Pathol. 2010 Jun; 176(6):2764-75.

Circulating interleukin-10: association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha

2010

Nitza Lahat, PhD
Authors : Amir O, Rogowski O, David M, Lahat N, Wolff R, Lewis BS.

Isr Med Assoc J. 2010 Mar;12(3):158-62.

In vitro tRNA Methylation Assay with the Entamoeba histolytica DNA and tRNA Methyltransferase Dnmt2 (Ehmeth) Enzyme

2010

Serge Ankri, PhD
Authors : Tovy A, Hofmann B, Helm M, Ankri S.

J Vis Exp. 2010 Oct 19;(44). pii: 2390. doi: 10.3791/2390.

Circulating interleukin-10: association with higher mortality in systolic heart failure patients with elevated tumor necrosis factor-alpha

2010

Nitza Lahat, PhD
Authors : Amir O, Rogowski O, David M, Lahat N, Wolff R, Lewis BS

Isr Med Assoc J. 2010 Mar;12(3):158-62

A distinct mechanism for the ABC transporter BtuCD-BtuF revealed by the dynamics of complex formation.

2010

Oded Lewinson, PhD
Authors : Lewinson O, Lee AT, Locher KP, Rees DC.

Nat Struct Mol Biol. 17, 332-8.

Extracting Cell-Type-Specific Gene Expression Differences from Complex Tissues.

2010

Shai Shen-Orr, PhD
Authors : Shen-Orr SS*, Tibshirani R*, Khatri P, Bodian DL, Staedtler F, Perry NM, Hastie T, Sarwal MM, Davis MM*, Butte AJ*.

Nature Methods 7, 287-9.

The MAPK/ERK and PI(3)K Pathways Additively Coordinate the Transcription of Recombination-Activating Genes in B Lineage Cells.

2010

Doron Melamed, PhD
Authors : Novak R, Jacob E, Haimovich J, Avni O, Melamed D.

Immunol 185, 3239 – 3247.

Protein denitrosylation: enzymatic mechanisms and cellular functions

2009

Moran Benhar, PhD
Authors : Benhar, M., Forrester, M.T., Stamler, J.S.

Nat. Rev. Mol. Cell Biol. 10:721-32.

Psoriasis patients generate increased serum levels of autoantibodies to tumor necrosis factor-alpha and interferon-alpha

2009

Nathan Karin, PhD
Authors : Bergman R, Ramon M, Wildbaum G, Avitan-Hersh E, Mayer E, Shemer A, Karin N.

J Dermatol Sci. 2009 Oct 1. Epub

The role of macrophage-derived IL-1 in induction and maintenance of angiogenesis

2009

Nitza Lahat, PhD
Authors : Carmi Y, Voronov E, Dotan S, Lahat N, Rahat MA, Fogel M, Huszar M, White MR, Dinarello CA, Apte RN.

J Immunol. 2009 Oct 1;183(7):4705-14.

Insights into the mechanism of DNA recognition by the methylated LINE binding protein EhMLBP of Entamoeba histolytica

2009

Serge Ankri, PhD
Authors : Lavi T, Siman-Tov R, Ankri S.

Mol Biochem Parasitol. 2009 Aug;166(2):117-25. Epub 2009 Mar 20.

A novel recombinant fusion protein encoding a 20-amino acid residue of the third extracellular (E3) domain of CCR2 neutralizes the biological activity of CCL2

2009

Nathan Karin, PhD
Authors : Izhak L, Wildbaum G, Zohar Y, Anunu R, Klapper L, Elkeles A, Seagal J, Yefenof E, Ayalon-Soffer M, Karin N

J Immunol. 2009 Jul 1;183(1):732-9

Selective autoantibody production against CCL3‭ ‬is associated with human type 1‭ ‬diabetes mellitus and serves as a novel biomarker for its diagnosis

2009

Nathan Karin, PhD
Authors : Shehadeh N‭, ‬Pollack S‭, ‬Wildbaum G‭, ‬Zohar Y‭, ‬Shafat I‭, ‬Makhoul R‭, ‬Daod E‭,‬

J Immunol‭. ‬2009‭ ‬Jun 15‭;‬182‭(‬12‭):‬8104-9

The effect of 100% oxygen on intestinal preservation and recovery following ischemia-reperfusion injury in rats

2009

Nitza Lahat, PhD
Authors : Sukhotnik I, Brod V, Lurie M, Rahat MA, Shnizer S, Lahat N, Mogilner JG, Bitterman H.

Crit Care Med. 2009 Mar;37(3):1054-61.

Transcriptional regulation of GATA3 in T helper cells by the integrated activities of transcription factors downstream of the interleukin-4 receptor and T cell receptor

2009

Orly Avni, PhD
Authors : Scheinman EJ, Avni O.

J Biol Chem. 2009 30;284(5):3037-48.

TOLL-like receptor ligands stimulate aberrant class switch recombination in early B cell precursors

2008

Doron Melamed, PhD
Authors : Edry E, Azulay-Debby H, Melamed D.

Int Immunol. 2008 Dec;20(12):1575-85. Epub 2008 Oct 29.

EhMLBP is an essential constituent of the Entamoeba histolytica epigenetic machinery and a potential drug target

2008

Serge Ankri, PhD
Authors : Lavi T, Siman-Tov R, Ankri S.

Mol Microbiol. 2008 Jul;69(1):55-66. Epub 2008 May 12

Hypoxia enhances lysosomal TNF-α degradation in mouse peritoneal macrophages

2008

Nitza Lahat, PhD
Authors : Lahat, N., Rahat, M. A., Kinarty, A., Weiss-Cerem, L., Pinchevski, S., Bitterman, H.

Am J Physiol Cell Physiol 295, C2-12.

What do unicellular organisms teach us about DNA methylation?

2008

Serge Ankri, PhD
Authors : Harony H

Trends Parasitol. 2008 May;24(5):205-9. Epub 2008 Apr 9. PMID: 18403268 [PubMed – in process]

Regulated protein denitrosylation by cytosolic and mitochondrial thioredoxins

2008

Moran Benhar, PhD
Authors : Benhar, M., Forrester, M.T., Hess, D.T., Stamler, J.S.

Science 320:1050-4

Trichostatin A regulates peroxiredoxin expression and virulence of the parasite Entamoeba histolytica.

2008

Serge Ankri, PhD
Authors : Isakov E, Siman-Tov R, Weber C, Guillen N

Mol Biochem Parasitol. 2008 Mar;158(1):82-94.

Progress and prospects of gene inactivation in Entamoeba histolytica.

2008

Serge Ankri, PhD
Authors : Abed M

Exp Parasitol. 2008 Feb;118(2):151-5

Class switch recombination: a friend and a foe.

2007

Doron Melamed, PhD
Authors : Edry E.

Clin Immunol. 2007 Jun;123(3):244-51.

Native and fragmented fibronectin oppositely modulate monocyte secretion of MMP-9

2007

Nitza Lahat, PhD
Authors : Marom, B., Rahat, M. A., Lahat, N., Weiss-Cerem, L., Kinarty, A., Bitterman, H.

J Leukoc Biol 81, 1466-1476.

SLP-76 mediates and maintains activation of the Tec family kinase ITK via the T cell antigen receptor-induced association between SLP-76 and ITK.

2007

Deborah Yablonski, PhD
Authors : Bogin Y, Ainey C, Beach D

Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6638-43.

Dual role of SLP-76 in mediating T cell receptor-induced activation of phospholipase C-gamma1.

2007

Deborah Yablonski, PhD
Authors : Beach D, Gonen R, Bogin Y, Reischl IG

J Biol Chem. 2007 Feb 2;282(5):2937-46. Epub 2006 Dec 4.

Read the Article

B cell receptor editing in tolerance and autoimmunity.

2007

Doron Melamed, PhD
Authors : Azulay-Debby H.

Front Biosci. 2007 Jan 1;12:2136-47.

Genome-wide analysis of mRNA polysomal profiles with spotted DNA microarrays.

2007

Doron Melamed, PhD
Authors : Arava Y.

Methods Enzymol. 2007;431:177-201

Coadministration of plasmid DNA constructs encoding an encephalitogenic determinant and IL-10 elicits regulatory T cell-mediated protective immunity in the central nervous system.

2006

Nathan Karin, PhD
Authors : Schif-Zuck S, Wildbaum G, Karin N.

J Immunol. 2006 Dec 1;177(11):8241-7.

Sensing DNA methylation in the protozoan parasite Entamoeba histolytica.

2006

Serge Ankri, PhD
Authors : Lavi T, Isakov E, Harony H, Fisher O, Siman-Tov R.

Mol Microbiol. 2006 Dec;62(5):1373-86.

Read the Article:

Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis.

2006

Doron Melamed, PhD
Authors : Melamed D, Messika O, Glass-Marmor L, Miller A.

Int Immunol. 2006 Sep;18(9):1355-62.

A Pak- and Pix-dependent branch of the SDF-1alpha signalling pathway mediates T cell chemotaxis across restrictive barriers.

2006

Deborah Yablonski, PhD
Authors : Volinsky N, Gantman A, Yablonski D.

Biochem J. 2006 Jul 1;397(1):213-22. PMID: 16515536 [PubMed – in process]

DNA methylation and targeting of LINE retrotransposons in Entamoeba histolytica and Entamoeba invadens.

2006

Serge Ankri, PhD
Authors : Harony H, Bernes S, Siman-Tov R, Ankri S.

Mol Biochem Parasitol. 2006 May;147(1):55-63. Epub 2006 Feb 23. PMID: 16530279 [PubMed � in process]

Pleiotropic phenotype in Entamoeba histolytica overexpressing DNA methyltransferase (Ehmeth).

2006

Serge Ankri, PhD
Authors : Fisher O, Siman-Tov R, Ankri S.

Mol Biochem Parasitol. 2006 May;147(1):48-54. Epub 2006 Feb 9. PMID: 16497397 [PubMed � in process]

Hypoxia reduces the output of matrix metalloproteinase-9 (MMP-9) in monocytes by inhibiting its secretion and elevating membranal association

2006

Nitza Lahat, PhD
Authors : Rahat, M. A., Marom, B., Bitterman, H., Weiss-Cerem, L., Kinarty, A., Lahat, N.

J Leukoc Biol 79, 706-718.

Antisense inhibition of Entamoeba histolytica cysteine proteases inhibits colonic mucus degradation

2006

Serge Ankri, PhD
Authors : Moncada D, Keller K, Ankri S, Mirelman D, Chadee K.

Gastroenterology. 2006 Mar;130(3):721-30. PMID: 16530514 [PubMed � indexed for MEDLINE]

Beneficial autoimmunity participates in the regulation of rheumatoid arthritis.

2006

Nathan Karin, PhD
Authors : Zohar Y, Wildbaum G, Karin N.

Front Biosci. 2006 Jan 1;11:368-79. Review. PMID: 16146738 [PubMed – indexed for MEDLINE]

The RNA polymerase II subunit Rpb4p mediates decay of a specific class of mRNAs.

2005

Doron Melamed, PhD
Authors : Lotan R, Bar-On VG, Harel-Sharvit L, Duek L, Melamed D, Choder M.

Genes Dev. 2005 Dec 15;19(24):3004-16. PMID: 16357218 [PubMed – indexed for MEDLINE]

Single point mutations in the zinc finger motifs of the human immunodeficiency virus type 1 nucleocapsid alter RNA binding specificities of the gag protein and enhance packaging and infectivity.

2005

Doron Melamed, PhD
Authors : Mark-Danieli M, Laham N, Kenan-Eichler M, Castiel A, Melamed D, Landau M, Bouvier NM, Evans MJ, Bacharach E.

J Virol. 2005 Jun;79(12):7756-67. PMID: 15919928 [PubMed – indexed for MEDLINE]

Molecular characterization of Entamoeba histolytica Rnase III and AGO2, two RNA interference hallmark proteins.

2005

Serge Ankri, PhD
Authors : Abed M, Ankri S.

Exp Parasitol. 2005 Jul;110(3):265-9. Epub 2005 Apr 7. PMID: 15955322 [PubMed � indexed for MEDLINE]

Targeted overexpression of IL-18 binding protein at the central nervous system overrides flexibility in functional polarization of antigen-specific Th2 cells.

2005

Nathan Karin, PhD
Authors : Schif-Zuck S, Westermann J, Netzer N, Zohar Y, Meiron M, Wildbaum G, Karin N.

Immunol. 2005 Apr 1;174(7):4307-15. PMID: 15778395 [PubMed – indexed for MEDLINE]

T cell receptor-induced activation of phospholipase C-gamma1 depends on a sequence-independent function of the P-I region of SLP-76.

2005

Deborah Yablonski, PhD
Authors : Gonen R, Beach D, Ainey C, Yablonski D.

J Biol Chem. 2005 Mar 4;280(9):8364-70. Epub 2004 Dec 28. PMID: 15623534 [PubMed – indexed for MEDLINE]

Naive, effector, and memory T lymphocytes efficiently scan dendritic cells in vivo: contact frequency in T cell zones of secondary lymphoid organs does not depend on LFA-1 expression and facilitates

2005

Nathan Karin, PhD
Authors : Westermann J, Bode U, Sahle A, Speck U, Karin N, Bell EB, Kalies K, Gebert A.

J Immunol. 2005 Mar 1;174(5):2517-24. PMID: 15728457 [PubMed – indexed for MEDLINE]

Antigen receptor signaling competence and the determination of B cell fate in B-lymphopoiesis.

2005

Doron Melamed, PhD
Authors : Keren Z, Melamed D.

Histol Histopathol. 2005 Jan;20(1):187-96. Review. PMID: 15578437 [PubMed – indexed for MEDLINE]

CD19 regulates positive selection and maturation in B lymphopoiesis: lack of CD19 imposes developmental arrest of immature B cells and consequential stimulation of receptor editing.

2005

Doron Melamed, PhD
Authors : Diamant E, Keren Z, Melamed D.

Blood ;105:3247-3254.

Entamoeba histolytica DNA methyltransferase (Ehmeth) is a nuclear matrix protein that binds EhMRS2, a DNA that includes a scaffold/matrix attachment region (S/MAR).

2005

Serge Ankri, PhD
Authors : Banerjee S, Fisher O, Lohia A, Ankri S.

Mol Biochem Parasitol. 2005 Jan;139(1):91-7. PMID: 15610823 [PubMed � indexed for MEDLINE]

Epigenetic and classical activation of Entamoeba histolytica heat shock protein 100 (EHsp100) expression.

2005

Serge Ankri, PhD
Authors : Bernes S, Siman-Tov R, Ankri S.

FEBS Lett;579:6395-6402.

T cell receptor-induced activation of phospholipase C-γ1 depends on a sequence-independent function of the P-I region of SLP-76.

2005

Deborah Yablonski, PhD
Authors : Gonen R, Beach D, Ainey C, Yablonski D.

J Biol Chem ;280:8364-8370.

Characterization of cytosine methylated regions and 5-cytosine DNA methyltransferase (Ehmeth) in the protozoan parasite Entamoeba histolytica.

2004

Serge Ankri, PhD
Authors : Fisher O, Siman-Tov R, Ankri S.

Nucleic Acids Res ;1:287-297.

Modification of ligandindependent B cell receptor tonic signals activates receptor editing in immature B lymphocytes.

2004

Doron Melamed, PhD
Authors : Keren Z, Diamant E, Ostrovsky O, Bengal E, Melamed D.

J Biol Chem ;279:13418-13424.

A failsafe mechanism for negative selection of isotype-switched B cell precursors is regulated by the Fas/FasL pathway

2003

Doron Melamed, PhD
Authors : Seagal J, Edry E, Keren Z, Leider N, Benny O, Machluf M, Melamed D.

J Exp Med ;198:1609-1619.

Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity.

2003

Nathan Karin, PhD
Authors : Wildbaum G, Nahir MA, Karin N.

Immunity;19:679-688.

T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes.

2002

Orly Avni, PhD
Authors : Avni O, Lee D, Macian F, Szabo SJ, Glimcher LH, Rao A.

Nat Immunol ;3:643-651.

Tr1 cell-dependent active tolerance blunts the pathogenic effects of determinant spreading.

2002

Nathan Karin, PhD
Authors : Wildbaum G, Netzer N, Karin N.

J Clin Invest ;110:701-710.

A PAK1-PIX-PKL complex is activated by the T-cell receptor independent of Nck, Slp-76 and LAT.

2001

Deborah Yablonski, PhD
Authors : Ku GM, Yablonski D, Manser E, Lim L, Weiss A.

EMBO Journal ;20:457-465.

Identification of a phospholipase C-γ1 (PLC- γ1) SH3 domain-binding site in SLP-76 required for T-cell receptor-mediated activation of PLC-γ1 and NFAT

2001

Deborah Yablonski, PhD
Authors : Yablonski D, Kadlecek T, Weiss A.

Mol Cell Biol ;21:4208-4218.

C-C chemokineencoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis.

2000

Nathan Karin, PhD
Authors : Youssef S, Maor G, Wildbaum G, Grabie N, Gour-Lavie A, Karin N.

J Clin Invest ;106:361-371.

Cell-type-restricted binding of the transcription factor NFAT to a distal IL-4 enhancer in vivo.

2000

Orly Avni, PhD
Authors : Agarwal S, Avni O, Rao A.

Immunity ;12:643-652.

T cell differentiation: a mechanistic view.

2000

Orly Avni, PhD
Authors : Avni O, Rao A.

Curr Opin Immunol; 12:654-659.

A systemic cytokine response defect stratifies older adults into distinct immune profiles.

1900

Shai Shen-Orr, PhD
Authors : Shen-Orr SS*, Furman D*, Kidd BA, Morgan A, Lovelace P, Rosenberg-Hasson Y, Maecker H, Mackey S, Dekker C, Butte AJ, Davis MM.

Submitted.

Read Full Post »

Cardiovascular Biology – A Bibliography of Research @Technion

Posted in Frontiers in Cardiology and Cardiovascular Disorders on May 27, 2014| Leave a Comment »

Cardiovascular Biology – A Bibliography of Research @Technion

Reporter: Aviva Lev-Ari, PhD, RN

Modulation of cardiac tissue electrophysiological properties with light-sensitive proteins

2014

Lior Gepstein, MD, PhD
Authors : Nussinovitch U, Shinnawi R, Gepstein L.

Cardiovasc Res. 2014 Feb 28. [Epub ahead of print]

The coagulation profile of preterm delivery

2014

Benjamin Brenner, MD
Authors : Keren-Politansky A, Breizman T, Brenner B, Sarig G, Drugan A.

Thromb Res. 2014 Apr;133(4):585-9. doi: 10.1016/j.thromres.2014.01.018. Epub 2014 Jan 22.

Procalcitonin and interleukin 6 for predicting blood culture positivity in sepsis

2014

Zaher S. Azzam, MD
Authors : Naffaa M, Makhoul BF, Tobia A, Kaplan M, Aronson D, Azzam ZS, Saliba W.

Am J Emerg Med. 2014 Jan 3. pii: S0735-6757(13)00917-0.

Brain natriuretic peptide at discharge as a predictor of 6-month mortality in acute decompensated heart failure

2014

Zaher S. Azzam, MD
Authors : Naffaa M, Makhoul BF, Tobia A, Jarous M, Kaplan M, Aronson D, Saliba W, Azzam ZS.

Am J Emerg Med. 2014 Jan;32(1):44-9.

Pomegranate extract (POMx) decreases the atherogenicity of serum and of human monocyte-derived macrophages (HMDM) in simvastatin-treated hypercholesterolemic patients: a double-blinded, placebo-controlled, randomized, prospective pilot study

2014

Michael Aviram, DSc
Authors : Hamoud S, Hayek T, Volkova N, Attias J, Moscoviz D, Rosenblat M, Aviram M.

Atherosclerosis. 2014 Jan;232(1):204-10.

Addition of pomegranate juice to statin inhibits cholesterol accumulation in macrophages: protective role for the phytosterol beta-sitosterol and for the polyphenolic antioxidant punicalagin

2013

Michael Aviram, DSc
Authors : Rosenblat M, Volkova N, Aviram M.

Harefuah. 2013 Sep;152(9):513-5, 565. Hebrew.

Derivation and cardiomyocyte differentiation of induced pluripotent stem cells from heart failure patients

2013

Lior Gepstein, MD, PhD
Authors : Zwi-Dantsis L, Huber I, Habib M, Winterstern A, Gepstein A, Arbel G, Gepstein L.

Eur Heart J. 2013 Jun;34(21):1575-86.

Haptoglobin genotype does not predict extent of coronary artery calcification in a prospective cohort of patients with type 2 diabetes

2013

Andrew Levy, MD, PhD
Authors : Jaffe R, Harari E, Gaspar T, Lewis BS, Rubinshtein R, Azencot M, Lavi I, Miller-Lotan R, Levy AP, Halon DA.

Int J Cardiol. 2013 Dec 4. pii: S0167-5273(13)02111-6.

Modeling of Arrhythmogenic Right Ventricular Cardiomyopathy with Human Induced Pluripotent Stem Cells

2013

Lior Gepstein, MD, PhD
Authors : Caspi O, Huber I, Gepstein A, Arbel G, Maizels L, Boulos M, Gepstein L.

Circ Cardiovasc Genet. 2013 Nov 7. [Epub ahead of print]

The mitochondria as a target for cardioprotection in acute myocardial ischemia

2013

Ofer Binah, PhD
Authors : Ertracht O, Malka A, Atar S, Binah O.

Pharmacol Ther. 2013 Nov 22. doi:pii: S0163-7258(13)00221-0.

Triglyceride accumulation in macrophages upregulates paraoxonase 2 (PON2) expression via ROS-mediated JNK/c-Jun signaling pathway activation

2013

Michael Aviram, DSc
Authors : Rosenblat M, Volkova N, Paland N, Aviram M.

Biofactors. 2012 Nov-Dec;38(6):458-69.

Vitamin E and diabetic nephropathy in mice model and humans

2013

Andrew Levy, MD, PhD
Authors : Farid N, Inbal D, Nakhoul N, Evgeny F, Miller-Lotan R, Levy AP, Rabea A.

World J Nephrol. 2013 Nov 6;2(4):111-124.

Coagulation and brain.

2013

Benjamin Brenner, MD
Authors : Brenner B, Gris JC.

Semin Thromb Hemost. 2013 Nov;39(8):847-8.

Chronic Akt1 Deficiency Attenuates Adverse Remodeling and Enhances Angiogenesis After Myocardial Infarction.

2013

Lior Gepstein, MD, PhD
Authors : Vandoorne K, Vandsburger MH, Raz T, Shalev M, Weisinger K, Biton I, Brumfeld V, Raanan C, Nevo N, Eilam R, Hemmings BA, Tzahor E, Harmelin A, Gepstein L, Neeman M.

Circ Cardiovasc Imaging. 2013 Oct 17.[Epub ahead of print] PubMed PMID: 24134954.

Hypercoagulability, parkinsonism, and Gaucher disease.

2013

Benjamin Brenner, MD
Authors : Rosenbaum H, Aharon-Peretz J, Brenner B.

Semin Thromb Hemost. 2013 Nov;39(8):928-34. Epub 2013 Oct 15. PubMed PMID: 24129683.

Pulmonary hypertension, rightventricular function, and clinical outcome in acute decompensated heart failure.

2013

J Card Fail. 2013 Oct;19(10):665-71.

Microvesicles of Women With Gestational Hypertension and Preeclampsia Affect Human Trophoblast Fate and Endothelial Function.

2013

Benjamin Brenner, MD
Authors : Shomer E, Katzenell S, Zipori Y, Sammour RN, Isermann B, Brenner B, Aharon A.

Hypertension. 2013 Nov;62(5):893-8.

Allosteric inhibitors of HMG-CoA reductase, the key enzyme involved in cholesterol biosynthesis

2013

Michael Aviram, DSc
Authors : Haber A, Abu-Younis Ali A, Aviram M, Gross Z.

Chem Commun (Camb). 2013 Aug 20. [Epub ahead of print] PubMed PMID: 23958894.

Haptoglobin 1-1 Genotype Is Associated With Poorer Cognitive Functioning in Type 2 Diabetic Elderly

2013

Andrew Levy, MD, PhD
Authors : Ravona-Springer R, Heymann A, Schmeidler J, Guerrero-Berroa E, Sano M, Preiss R, Koifman K, Hoffman H, Levy A, Silverman JM, Schnaider-Beeri M.

Diabetes Care. 2013 Aug 29. [Epub ahead of print] PubMed PMID: 23990521.

Hyponatraemia predicts the acute (type 1) cardio-renal syndrome

2013

Zaher S. Azzam, MD
Authors : Aronson D, Darawsha W, Promyslovsky M, Kaplan M, Abassi Z, Makhoul BF ,Goldberg A, Azzam ZS.

Eur J Heart Fail. 2013 Jul 24. [Epub ahead of print] PubMed PMID: 23883652.

Interleukin-6 at discharge predicts all-cause mortality in patients with sepsis

2013

Zaher S. Azzam, MD
Authors : Naffaa M, Makhoul BF, Tobia A, Kaplan M, Aronson D, Saliba W, Azzam ZS.

Am J Emerg Med. 2013 Sep;31(9):1361-4.

Intraventricular haemorrhage in preterm infants – Can we improve outcome by addressing coagulation?

2013

Benjamin Brenner, MD
Authors : Kuperman AA, Brenner B, Kenet G.

J Matern Fetal Neonatal Med. 2013 Aug 23. [Epub ahead of print] PubMed PMID: 23968273.

Metformin inhibits macrophage cholesterol biosynthesis rate: Possible role for metformin-induced oxidative stress

2013

Michael Aviram, DSc
Authors : Koren-Gluzer M, Aviram M, Hayek T.

Biochem Biophys Res Commun. 2013 Sep 27;439(3):396-400.

Modeling Catecholaminergic Polymorphic Ventricular Tachycardia using Induced Pluripotent Stem Cell-derived Cardiomyocytes

2013

Ofer Binah, PhD
Authors : Novak A, Lorber A, Itskovitz-Eldor J, Binah O.

Rambam Maimonides Med J. 2012 Jul 31;3(3):e0015.

Monocyte-macrophage membrane possesses free radicals scavenging activity: stimulation by polyphenols or by paraoxonase 1 (PON1)

2013

Michael Aviram, DSc
Authors : Rosenblat M, Elias A, Volkova N, Aviram M.

Free Radic Res. 2013 Apr;47(4):257-67.

Patient selection and vitamin E treatment in diabetes mellitus

2013

Andrew Levy, MD, PhD
Authors : Goldenstein H, Levy NS, Lipener YT, Levy AP.

Expert Rev Cardiovasc Ther. 2013 Mar;11(3):319-26.

Pomegranate for your cardiovascular health

2013

Michael Aviram, DSc
Authors : Aviram M, Rosenblat M.

Rambam Maimonides Med J. 2013 Apr 30;4(2):e0013.

Reproductive organ involvement in non-Hodgkin lymphoma during pregnancy: a systematic review

2013

Benjamin Brenner, MD
Authors : Horowitz NA, Benyamini N, Wohlfart K, Brenner B, Avivi I.

Lancet Oncol. 2013 Jun;14(7):e275-82.

The association between poor ovarian response and thrombophilia in assisted reproduction

2013

Benjamin Brenner, MD
Authors : Younis JS, Ben-Ami M, Izhaki I, Jadaon J, Brenner B, Sarig G.

Eur J Obstet Gynecol Reprod Biol. 2013 Jan;166(1):65-9.

The role of fibrin matrices and tissue factor in early-term trophoblast proliferation and spreading.

2013

Benjamin Brenner, MD
Authors : Snir A, Brenner B, Paz B, Ohel G, Lanir N.

Thromb Res. 2013 Sep 1. [Epub ahead of print] PubMed PMID: 24041635.

Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion

2013

Michael Aviram, DSc
Authors : Aviram M, Vaya J.

Curr Opin Lipidol. 2013 Aug;24(4):339-44.

Acute obstructive jaundice and chronic cirrhosis protect against the adverse renal effects of pneumoperitoneum: role of nitric oxide

2013

Zaher S. Azzam, MD
Authors : Naffaa M, Abu-Saleh N, Awad H, Khamaysi I, Karram T, Azzam ZS, Abassi Z, Bishara B.

Surg Endosc. 2013 Jul;27(7):2517-25.

Paraoxonase1 (PON1) reduces insulin resistance in mice fed a high-fat diet, and promotes GLUT4 overexpression in myocytes, via the IRS-1/Akt pathway.

2013

Michael Aviram, DSc
Authors : Koren-Gluzer M, Aviram M, Hayek T.

Atherosclerosis. 2013 Jul;229(1):71-8.

Is the Hp 2-2 diabetic mouse model a good model to study diabetic nephropathy?

2013

Andrew Levy, MD, PhD
Authors : Nakhoul F, Nakhoul N, Asleh R, Miller-Lotan R, Levy AP.

Diabetes Res Clin Pract. 2013 Jun;100(3):289-97.

Paraoxonase 1 (PON1) reduces macrophage inflammatory responses.

2013

Michael Aviram, DSc
Authors : Aharoni S, Aviram M, Fuhrman B.

Atherosclerosis. 2013 Jun;228(2):353-61.

Date (Phoenix dactylifera L.) fruit soluble phenolics composition and anti-atherogenic properties in nine Israeli varieties

2013

Michael Aviram, DSc
Authors : Borochov-Neori H, Judeinstein S, Greenberg A, Volkova N, Rosenblat M, Aviram M.

J Agric Food Chem. 2013 May 8;61(18):4278-86.

Intraventricular hemorrhage in preterm infants and coagulation–ambivalent perspectives?

2013

Thromb Res. 2013 Jan;131 Suppl 1:S35-8. doi: 10.1016/S0049-3848(13)70018-5. Review.

Placenta-derived microparticles.

2013

Benjamin Brenner, MD
Authors : Aharon A, Brenner B.

Thromb Res. 2013 Jan;131 Suppl 1:S22-4. doi: 10.1016/S0049-3848(13)70014-8. Review.

Pomegranate phytosterol (β-sitosterol) and polyphenolic antioxidant (punicalagin) addition to statin, significantly protected against macrophage foam cells formation.

2013

Michael Aviram, DSc
Authors : Rosenblat M, Volkova N, Aviram M.

Atherosclerosis. 226, 110-7

Triglyceride accumulation in macrophages upregulates paraoxonase 2 (PON2) expression via ROS-mediated JNK/c-Jun signaling pathway activation.

2013

Michael Aviram, DSc
Authors : Rosenblat M, Volkova N, Paland N, and Aviram M.

BioFactors. 38,458-469

Paraoxonase activity and expression is modulated by therapeutics in experimental rat nonalcoholic Fatty liver disease

2012

Michael Aviram, DSc
Authors : Hussein O, Zidan J, Abu Jabal K, Shams I, Szvalb S, Grozovski M, Bersudsky I, Karry R, Aviram M.

Int J Hepatol. 2012;2012:265305.

Characterization of negatively charged phospholipids and cell origin of microparticles in women with gestational vascular complications

2012

Benjamin Brenner, MD
Authors : Katzenell S, Shomer E, Zipori Y, Zylberfisz A, Brenner B, Aharon A.

Thromb Res. 2012 Apr 23. [Epub ahead of print]

Importance of Ventricular Tachycardia Storms Not Terminated by Implantable Cardioverter Defibrillators Shocks in Patients With CASQ2 Associated Catecholaminergic Polymorphic Ventricular Tachycardia

2012

Lior Gepstein, MD, PhD
Authors : Marai I, Khoury A, Suleiman M, Gepstein L, Blich M, Lorber A, Boulos M.

Am J Cardiol. 2012. 110(1):72-6.

Haptoglobin genotype and its role in determining heme-iron mediated vascular disease.

2012

Andrew Levy, MD, PhD
Authors : Goldenstein H, Levy NS, Levy AP.

Pharmacol Res. 2012 ;66(1):1-6.

HDL dysfunction in diabetes: causes and possible treatments.

2012

Andrew Levy, MD, PhD
Authors : Farbstein D, Levy AP.

Expert Rev Cardiovasc Ther. 2012 Mar;10(3):353-61.

Urokinase-type plasminogen activator downregulates paraoxonase 1 expression in hepatocytes by stimulating peroxisome proliferator-activated receptor-� nuclear export.

2012

Michael Aviram, DSc
Authors : Khateeb J, Kiyan Y, Aviram M, Tkachuk S, Dumler I, Fuhrman B.

Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):449-58.

CPVT-specific cardiomyocytes generated from induced pluripotent stem cells are arrhythmogenic.

2012

Ofer Binah, PhD
Authors : Novak A, Barad L, Zeevi-Levin N, Shtreichman R, Gherghiceanu M, Popescu LM, Lorber A, Itskovitz-Eldor J, Binah O.

J Cell Mol Med 16, 468-82.

Efficient Engineering of Vascularized Ectopic Bone from Human Embryonic Stem Cell-Derived Mesenchymal Stem Cells.

2012

Joseph Itskovitz-Eldor, MD, DSc
Authors : Domev H, Amit M, Dar A, Itskovitz-Eldor J.

Tiss Eng. 2012 (in press)

Human embryonic and induced pluripotent stem cell-derived cardiomyocytes exhibit beat rate variability and power-law behavior.

2012

Ofer Binah, PhD
Authors : Mandel Y, Weissman A, Schick R, Barad L, Novak A, Meiry G, Goldberg S, Lorber A, Rosen MR, Itskovitz-Eldor J, Binah O.

Circulation 125, 883-93.

Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human induced pluripotent stem cells.

2012

Lior Gepstein, MD, PhD
Authors : Itzhaki I, Maizels L, Huber I, Gepstein A, Arbel A, Caspi O, Miller L, Belhassen B, Nof E, Glikson M, Gepstein L.

J Am Coll Cardiol. 60, 990-1000.

Multipotent vasculogenic pericytes from human pluripotent stem cells promote recovery of murine ischemic limb.

2012

Joseph Itskovitz-Eldor, MD, DSc
Authors : Dar A, Domev H, Ben-Yosef O, Tzukerman M, Zeevi-Levin N, Novak A, Germanguz I, Amit M, Itskovitz-Eldor J.

Circulation 125, 87-99.

Pomegranate Protection against Cardiovascular Diseases. Evid Based Complement Alternat Med (eCAM).

2012

Michael Aviram, DSc
Authors : Aviram M and Rosenblat M.

12:382763, doi: 10.1155/2012/382763.

Vasopressin-2 Receptor Antagonists Attenuate the Ability of the Lungs to Clear Edema in an Experimental Model.

2012

Zaher S. Azzam, MD
Authors : Guetta J, Klorin G, Tal R, Berger G, Ismael-Badarneh R, Bishara B, Sabo E, Abassi Z, Azzam ZS.

Am J Respir Cell Mol Biol. 47, 583-8.

Injection of paraoxonase 1 (PON1) to mice stimulates their HDL and macrophage antiatherogenicity

2011

Michael Aviram, DSc
Authors : Rosenblat M, Volkova N, Aviram M.

Biofactors. 2011 Nov-Dec;37(6):462-7.

A combined cell therapy and in-situ tissue-engineering approach for myocardial repair.

2011

Lior Gepstein, MD, PhD
Authors : Habib M, Shapira-Schweitzer K, Caspi O, Gepstein A, Arbel G, Aronson D,

Biomaterials. 2011 Oct;32(30):7514-23.

Intraventricular hemorrhage in preterm infants: coagulation perspectives

2011

Benjamin Brenner, MD
Authors : Kuperman AA, Kenet G, Papadakis E, Brenner B.

Semin Thromb Hemost. 2011 Oct;37(7):730-6.

Cardiomyocytes derived from human embryonic and induced pluripotent stem cells: comparative ultrastructure.

2011

Ofer Binah, PhD
Authors : Gherghiceanu M, Barad L, Novak A, Reiter I, Itskovitz-Eldor J, Binah O,

J Cell Mol Med. 2011 Aug 24. [Epub ahead of print]

The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates �≤-cell

2011

Michael Aviram, DSc
Authors : Koren-Gluzer M, Aviram M, Meilin E, Hayek T.

Atherosclerosis. 2011 Aug 4. [Epub ahead of print]

Consumption of pomegranate decreases serum oxidative stress and reduces disease activity in patients with active rheumatoid arthritis: a pilot study.

2011

Michael Aviram, DSc
Authors : Balbir-Gurman A, Fuhrman B, Braun-Moscovici Y, Markovits D, Aviram M.

Isr Med Assoc J. 2011 Aug;13(8):474-9.

Pomegranate juice protects macrophages from triglyceride accumulation: inhibitory effect on DGAT1 activity and on triglyceride biosynthesis.

2011

Ann Nutr Metab. 2011; 58(1):1-9.

Paraoxonase 1 (PON1) inhibits monocyte-to-macrophage differentiation

2011

Michael Aviram, DSc
Authors : Rosenblat M, Volkova N, Ward J, Aviram M.

Atherosclerosis. 2011; 219(1):49-56.

MMP expression in leaking filtering blebs and tears after glaucoma filtering surgery.

2011

Nitza Lahat, PhD
Authors : Mathalone N, Marmor S, Rahat MA, Lahat N, Oron Y, Geyer O.

Jul;249(7):1047-55.

Nitric oxide: a key factor behind the dysfunctionality of endothelial progenitor cells in diabetes mellitus type-2.

2011

Benjamin Brenner, MD
Authors : Robicsek O, Makhoul B, Klein E, Brenner B, Sarig G.

Cardiovasc Res. 2011 Jul 1;91(1):9-15.

Sequential phosphorylation of SLP-76 at tyrosine 173 is required for activation of T and mast cells.

2011

Deborah Yablonski, PhD
Authors : Sela M, Bogin Y, Beach D, Oellerich T, Lehne J, Smith-Garvin JE, Okumura M,

EMBO J. 2011 Jul 1;30(15):3160-72.

Involvement of microparticles in diabetic vascular complications.

2011

Benjamin Brenner, MD
Authors : Tsimerman G, Roguin A, Bachar A, Melamed E, Brenner B, Aharon A.

Thromb Haemost. 2011 Jun 28;106(2). [Epub ahead of print]

Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype

2011

Andrew Levy, MD, PhD
Authors : Farbstein D, Blum S, Pollak M, Asaf R, Viener HL, Lache O, Asleh R,

Atherosclerosis. 2011 ;219(1):240-4.

Genetics of redox systems and their relationship with cardiovascular disease.

2011

Curr Atheroscler Rep. 2011; 13(3):215-24.

Circadian pattern of life-threatening ventricular arrhythmia in patients with sleep-disordered breathing and implantable cardioverter-defibrillators.

2011

Lior Gepstein, MD, PhD
Authors : Zeidan-Shwiri T, Aronson D, Atalla K, Blich M, Suleiman M, Marai I, Gepstein, L, Lavie L, Lavie P, Boulos M.

2011 May;8(5):657-62.

Effects of chronic rosiglitazone treatment on renal handling of salt and water in rats with volume-overload congestive heart failure.

2011

Aaron Hoffman, MD
Authors : Goltsman I, Wang X, Lavallie ER, Diblasio-Smith EA, Ovcharenko E, Hoffman A,

Circ Heart Fail. 2011 May 1;4(3):345-54.

Haptoglobin genotype and the iron hypothesis of atherosclerosis.

2011

Atherosclerosis. 2011 May;216(1):17-8.

Activation of coagulation in amniotic fluid during normal human pregnancy.

2011

Benjamin Brenner, MD
Authors : Sarig G, Klil-Drori AJ, Chap-Marshak D, Brenner B, Drugan A.

Thromb Res. 2011 Apr 18. [Epub ahead of print]

Paraoxonase 1 protects macrophages from atherogenicity of a specific triglyceride isolated from human carotid lesion.

2011

Michael Aviram, DSc
Authors : Tavori H, Aviram M, Khatib S, Musa R, Mannheim D, Karmeli R, Vaya J.

Free Radic Biol Med. 2011 Apr 13. [Epub ahead of print]

An assay to evaluate heparanase procoagulant activity.

2011

Benjamin Brenner, MD
Authors : Nadir Y, Kenig Y, Drugan A, Shafat I, Brenner B.

Thromb Res. 2011 Apr 7. [Epub ahead of print]

Air travel and the risk of thromboembolism.

2011

Intern Emerg Med. 2011 Apr;6(2):113-6.

Calcium handling in human induced pluripotent stem cell derived

2011

Lior Gepstein, MD, PhD
Authors : Itzhaki I, Rapoport S, Huber I, Mizrahi I, Zwi-Dantsis L, Arbel G, Schiller

PLoS One. 2011 Apr 1;6(4):e18037.

Calcium handling in human induced pluripotent stem cell derived cardiomyocytes.

2011

Lior Gepstein, MD, PhD
Authors : Itzhaki I, Rapoport S, Huber I, Mizrahi I, Zwi-Dantsis L, Arbel G, Schiller J, Gepstein L.

PLoS One. 2011 Apr 1;6(4):e18037.

Scalable production of cardiomyocytes derived from c-Myc free induced pluripotent stem cells.

2011

Lior Gepstein, MD, PhD
Authors : Zwi-Dantsis L, Mizrahi I, Arbel G, Gepstein A, Gepstein L.

Tissue Eng Part A. 2011 Apr;17(7-8):1027-37.

Effects of Chronic Rosiglitazone Treatment on Renal Handling of Salt and Water in Rats with Volume-Overload Congestive Heart

2011

Aaron Hoffman, MD
Authors : Goltsman I, Wang X, Lavallie ER, Diblasio-Smith EA, Ovcharenko E, Hoffman A, Abassi Z, Feuerstein GZ, Winaver J.

Circ Heart Fail. 2011 Mar 11. [Epub ahead of print]

Insulin increases macrophage triglyceride accumulation under diabetic conditions through the down regulation of hormone sensitive lipase and adipose triglyceride lipase.

2011

Biofactors. 2011 Mar; 37(2): 95-103.

Insulin increases macrophage triglyceride accumulation under diabetic conditions through the down regulation of hormone sensitive lipase and adipose triglyceride lipase.

2011

Michael Aviram, DSc
Authors : Meilin E, Aviram M, Hayek T.

Biofactors. 2011 Feb 22. doi: 10.1002/biof.144. [Epub ahead of print]

Microparticles and pregnancy complications.

2011

Benjamin Brenner, MD
Authors : Aharon A, Brenner B.

Thromb Res. 2011 Feb;127 Suppl 3:S67-71.

Haptoglobin genotype and the iron hypothesis of atherosclerosis.

2011

Andrew Levy, MD, PhD
Authors : Viener HL, Levy AP.

Atherosclerosis. 2011 Jan 28. [Epub ahead of print]

Modelling the long QT syndrome with induced pluripotent stem cells.

2011

Lior Gepstein, MD, PhD
Authors : Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, Boulos M, Gepstein L.

Nature. 2011 Jan 16. [Epub ahead of print]

Pomegranate Juice Protects Macrophages from Triglyceride Accumulation: Inhibitory Effect on DGAT1 Activity and on Triglyceride Biosynthesis.

2011

Michael Aviram, DSc
Authors : Rosenblat M, Aviram M.

Ann Nutr Metab. 2011 Jan 6;58(1):1-9.

Aortocaval fistula in rat: a unique model of volume-overload congestive heart failure and cardiac hypertrophy.

2011

Aaron Hoffman, MD
Authors : Abassi Z, Goltsman I, Karram T, Winaver J, Hoffman A.

J Biomed Biotechnol. 2011;2011:729497.

Cardiomyocytes generated from CPVT(D307H) patients are arrhythmogenic in response to �≤-adrenergic stimulation.

2011

Ofer Binah, PhD
Authors : Novak A, Barad L, Zeevi-Levin N, Shick R, Shtreichman R, Lorber A, Itskovitz-Eldor J, Binah O.

J Cell Mol Med. 2011 [Epub ahead of printy

Extracellular Signal-Regulated Kinases 1 and 2 Regulate the Balance Between Eccentric and Concentric Cardiac Growth.

2011

Izhak Kehat, MD PhD
Authors : Kehat I, Davis J, Tiburcy M, Accornero F, Saba-El-Leil MK, Maillet M, York AJ, Lorenz JN, Zimmermann WH, Meloche S, Molkentin JD.

Circ Res. 108, 176-83.

Modulation of chromatin position and gene expression by HDAC4 through interaction with nucleoporins.

2011

Izhak Kehat, MD PhD
Authors : Kehat I, Accornero F, Aronow BJ, Molkentin JD.

J Cell Biol. 193, 21-9.

Sepsis Impairs Alveolar Epithelial Function by Down-regulating Na,K-ATPase Pump.

2011

Zaher S. Azzam, MD
Authors : Berger G, Klorin G, Guetta J, Badarneh R, Brod V, Abu saleh N, Bitterman H, Azzam, ZS.

Am J Physiol Lung Cell Mol Physiol 30, L23-30.

The cardioprotective efficacy of TVP1022 in a rat model of ischaemia/reperfusion.

2011

Ofer Binah, PhD
Authors : Ertracht O, Liani E, Bachner-Hinenzon N, Bar-Am O, Frolov L, Ovcharenko E,

Br J Pharmacol. 2011 Jun;163(4):755-69.

The cardioprotective efficacy of TVP1022 in a rat model of myocardial infarction: Involvement of the glycogen synthase kinase 3β pathway and the mitochondrial permeability transition pore.

2011

Ofer Binah, PhD
Authors : Ertracht O, Liani E, Bachner N, Bar-Am O, Ovcharenko E, Awad H, Barac Y, Frolov L, Amit T, Abassi Z, Adam D, Youdim M, Binah O.

Br J Pharmacol 163, 755-69.

Oxide: a Key Factor behind the Dysfunctionality of Endothelial Progenitor Cells in Diabetes Mellitus Type-2.

2010

Benjamin Brenner, MD
Authors : Hamed S, Brenner B, Roguin A. Nitric

Cardiovasc Res. 2010 Dec 24. [Epub ahead of print]

Circadian Pattern of Life-Threatening Ventricular Arrhythmia in Patients with Sleep-Disordered Breathing and Implantable Cardioverter-Defibrillators.

2010

Lior Gepstein, MD, PhD
Authors : Zeidan-Shwiri T, Aronson D, Atalla K, Blich M, Suleiman M, Marai I, Gepstein L, Lavie L, Lavie P, Boulos M.

Heart Rhythm. 2010 Dec 22. [Epub ahead of print]

Enhanced reprogramming and cardiac differentiation of human keratinocytes derived from plucked hair follicles, using a single excisable lentivirus.

2010

Ofer Binah, PhD
Authors : Novak A, Shtrichman R, Germanguz I, Segev H, Zeevi-Levin N, Fishman B, Mandel YE, Barad L, Domev H, Kotton D, Mostoslavsky G, Binah O, Itskovitz-Eldor J.

Cell Reprogram. 2010 Dec;12(6):665-78.

Scalable production of cardiomyocytes derived from induced pluripotent stem (iPS) cells without c-Myc.

2010

Lior Gepstein, MD, PhD
Authors : Zwi L, Mizrahi I, Arbel G, Gepstein A, Gepstein L.

Tissue Eng Part A. 2010 Nov 19. [Epub ahead of print]

Antioxidant vitamins and their use in preventing cardiovascular disease.

2010

Andrew Levy, MD, PhD
Authors : Farbstein D, Kozak-Blickstein A, Levy AP.

Molecules. 2010 Nov 9; 15(11):8098-110.

Air travel and the risk of thromboembolism.

2010

Benjamin Brenner, MD
Authors : Gavish I, Brenner B.

Intern Emerg Med. 2010 Nov 6. [Epub ahead of print]

Clinical and electrophysiologic outcomes of patients undergoing percutaneous endocardial ablation of scar-related ventricular tachycardia: a single-center experience.

2010

Lior Gepstein, MD, PhD
Authors : Marai I, Suleiman M, Blich M, Zeidan-Shwiri T, Gepstein L, Boulos M.

Isr Med Assoc J. 2010 Nov;12(11):667-70.

Heparanase enhances the generation of activated factor X in the presence of tissue factor and activated factor VII.

2010

Benjamin Brenner, MD
Authors : Nadir Y, Brenner B, Fux L, Shafat I, Attias J, Vlodavsky I.

Haematologica. 2010 Nov;95(11):1927-34.

A Combined Gene and Cell Therapy Approach for Restoration of Conduction.

2010

Lior Gepstein, MD, PhD
Authors : Hofshi A, Itzhaki I, Gepstein A, Arbel G, Gross GJ, Gepstein L.

Heart Rhythm 2010, Oct 13. [Epub ahead of print]

Haptoglobin phenotype in women with preeclampsia.

2010

Andrew Levy, MD, PhD
Authors : Sammour RN, Nakhoul FM, Levy AP, Miller-Lotan R, Nakhoul N, Awad HR, Gonen R, Ohel G.

Endocrine. 2010 Oct;38(2):303-8. Epub 2010 Oct 23.

Human carotid lesion linoleic acid hydroperoxide inhibits paraoxonase 1 (PON1) activity via reaction with PON1 free sulfhydryl cysteine 284

2010

Michael Aviram, DSc
Authors : Tavori H, Aviram M, Khatib S, Musa R, Mannheim D, Karmeli R, Vaya J.

Free Radic Biol Med. 2010 Oct 28. [Epub ahead of print]

In Vivo Assessment of the lectrophysiological Integration and Arrhythmogenic Risk of Myocardial Cell Transplantation Strategies.

2010

Lior Gepstein, MD, PhD
Authors : Gepstein L, Ding C, Rehemedula D, Wilson EE, Yankelson L, Caspi O, Gepstein A, Huber I, Olgin JE.

Stem Cells. 2010 Oct 19. [Epub ahead of print]

Involvement of heparanase in vaginal and cesarean section deliveries.

2010

Benjamin Brenner, MD
Authors : Nadir Y, Kenig Y, Drugan A, Zcharia E, Brenner B.

Thromb Res. 2010 Oct 5. [Epub ahead of print]

Macrophage endoplasmic reticulum (ER) proteins and reducing elements stabilize paraoxonase 2 (PON2)

2010

Michael Aviram, DSc
Authors : Rosenblat M, Volkova N, Aviram M.

Atherosclerosis.2010 Oct 29. [Epub ahead of print]

Prolonged travel and venous thromboembolism findings from the RIETE registry.

2010

Benjamin Brenner, MD
Authors : Tsoran I, Saharov G, Brenner B, Barr�n M, Vald�s V, de la Roca Toda M, Monreal M.

Thromb Res. 2010 Oct;126(4):287-91.

Hypercoagulability and recurrent miscarriages.

2010

Benjamin Brenner, MD
Authors : Brenner B.

Clin Adv Hematol Oncol. 2010 Jul;8(7):467-9.

Hypoxia causes connexin 43 internalization in neonatal rat ventricular myocytes

2010

Ofer Binah, PhD
Authors : Danon A, Zeevi-Levin N, Pinkovich DY, Michaeli T, Berkovich A, Flugelman M, Eldar YC, Rosen MR, Binah O.

Gen Physiol Biophys. 2010 Sep;29(3):222-33.

Layer-specific strain analysis by speckle tracking echocardiography reveals differences in left ventricular function between rats and humans.

2010

Ofer Binah, PhD
Authors : Bachner-Hinenzon N, Ertracht O, Leitman M, Vered Z, Shimoni S, Beeri R, Binah O, Adam D.

Am J Physiol Heart Circ Physiol. 2010 Sep;299(3):H664-72.

Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against apoptosis

2010

Michael Aviram, DSc
Authors : Fuhrman B, Gantman A, Aviram M.

Atherosclerosis. 2010 Jul;211(1):61-8.

Paraoxonase 1 deficiency in mice is associated with reduced steroid biosynthesis: effects on HDL binding, cholesteryl ester accumulation and scavenger receptor type BI expression

2010

Michael Aviram, DSc
Authors : Gamliel-Lazarovich A, Gantman A, Shiner M, Coleman R, Aviram M, Keidar S.

Atherosclerosis. 2010 Jul;211(1):130-5.

Pomegranate juice (PJ) consumption antioxidative properties on mouse macrophages, but not PJ beneficial effects on macrophage cholesterol and triglyceride metabolism, are mediated via PJ-induced stimulation of macrophage PON2. Atherosclerosis.

2010

Michael Aviram, DSc
Authors : Rosenblat M, Volkova N, Aviram M.

2010 Sep;212(1):86-92.

The genetics of vascular complications in diabetes mellitus

2010

Andrew Levy, MD, PhD
Authors : Farbstein D, Levy AP.

Cardiol Clin. 2010 Aug;28(3):477-96.

Layer-specific assessment of left ventricular function by utilizing wavelet de-noising: a validation study

2010

Ofer Binah, PhD
Authors : Bachner-Hinenzon N, Ertracht O, Lysiansky M, Binah O, Adam D

Med Biol Eng Comput. 2010 Jul 20. [Epub ahead of print]

Heparanase enhances factor Xa generation in the presence of tissue-factor and factor VIIa

2010

Benjamin Brenner, MD
Authors : Nadir Y, Brenner B, Fux L, Shafat I, Attias J, Vlodavsky I

Haematologica. 2010 Jul 15. [Epub ahead of print]

Prolonged travel and venous thromboembolism findings from the RIETE

2010

Benjamin Brenner, MD
Authors : Tsoran I, Saharov G, Brenner B, Barr�n M, Vald�s V, de la Roca Toda M, Monreal M.

Thromb Res. 2010 Jul 11. [Epub ahead of print]

Methods for human embryonic stem cells derived cardiomyocytes cultivation, genetic

2010

Lior Gepstein, MD, PhD
Authors : Arbel G, Caspi O, Huber I, Gepstein A, Weiler-Sagie M, Gepstein L.

Methods Mol Biol. 2010;660:85-95.

Red wine consumption improves in vitro migration of endothelial progenitor cells in young, healthy individuals

2010

Benjamin Brenner, MD
Authors : Hamed S, Alshiek J, Aharon A, Brenner B, Roguin A

Am J Clin Nutr. 2010 Jul;92(1):161-9.

Increased macrophage cholesterol biosynthesis and decreased cellular paraoxonase 2 (PON2) expression in Delta6-desaturase knockout (6-DS KO) mice: beneficial effects of arachidonic acid. Atherosclerosis.

2010

Michael Aviram, DSc
Authors : Rosenblat M, Volkova N, Roqueta-Rivera M, Nakamura MT, Aviram M.

2010 Jun;210(2):414-21.

Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype

2010

Andrew Levy, MD, PhD
Authors : Blum S, Vardi M, Brown JB, Russell A, Milman U, Shapira C, Levy NS,

Pharmacogenomics. 2010 May;11(5):675-84.

Modulation of excessive neuronal activity by fibroblasts: potential use in treatment of Parkinson’s disease.

2010

Lior Gepstein, MD, PhD
Authors : Finberg JP, Gluzman Z, Reshef M, Loboda Y, Mohsen U, Bressler-Stramer T, Miari R, Gepstein L, Marom S, Feld Y.

Restor Neurol Neurosci. 2010 Jan 1;28(6):803-15.

Molecular pathways underlying cardiac remodeling during pathophysiologic stimulation.

2010

Izhak Kehat, MD PhD
Authors : Kehat I, Molkentin JD.

Circulation. 122, 2727-35.

Paraoxonase 1 attenuates human plaque atherogenicity: relevance to the enzyme lactonase activity.

2010

Michael Aviram, DSc
Authors : Tavori H, Vaya J, Aviram M.

Adv Exp Med Biol. 2010;660:99-111.

Paraoxonase 1 interactions with HDL, antioxidants and macrophages regulate atherogenesis – a protective role for HDL phospholipids.

2010

Michael Aviram, DSc
Authors : Efrat M, Aviram M.

Adv Exp Med Biol. 2010;660:153-66.

Suspension culture of undifferentiated human embryonic stem cells.

2010

Stem Cell Rev 6, 248-59.

The Physiological and Molecular Effects of Elevated CO2 Levels.

2010

Zaher S. Azzam, MD
Authors : Azzam ZS, Sharabi K, Guetta J, Bank EM, Gruenbaum Y.

Cell Cycle 9, 1528-1532.

Involvement of‭ ‬Heparanase in early pregnancy losses

2009

Benjamin Brenner, MD
Authors : Nadir Y‭, ‬Henig I‭, ‬Naroditzky I‭, ‬Paz B‭, ‬Vlodavsky I‭, ‬Brenner B‭.

Thromb Res‭. ‬2009‭ ‬Dec 21‭. [‬Epub ahead of print‭]

Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells

2009

Ofer Binah, PhD
Authors : Germanguz I‭, ‬Sedan O‭, ‬Zeevi-Levin N‭, ‬Shtreichman R‭, ‬Barak E‭, ‬Ziskind A‭, ‬Eliyahu S‭, ‬Meiry G‭, ‬Amit M‭, ‬Itskovitz-Eldor J‭, ‬Binah O‭.

J Cell Mol Med‭. ‬2009‭ ‬Dec 11‭. [‬Epub ahead of print‭]

Increased macrophage cholesterol biosynthesis and decreased cellular paraoxonase 2‭ (‬PON2‭)‬ expression in Delta6-desaturase knockout‭ (‬6-DS KO‭) ‬mice‭: ‬Beneficial effects of arachidonic acid

2009

Michael Aviram, DSc
Authors : Rosenblat M‭, ‬Volkova N‭, ‬Roqueta-Rivera M‭, ‬Nakamura MT‭, ‬Aviram M‭. ‬

Atherosclerosis‭. ‬2009‭ ‬Dec 1‭. [‬Epub ahead of print‭]

High glucose stimulates macrophage SR-BI expression and induces a switch in its activity from cholesterol efflux to cholesterol influx

2009

Michael Aviram, DSc
Authors : Gantman A, Fuhrman B, Aviram M, Hayek T.

Biochem Biophys Res Commun. 2009 Nov 23.

Nitric oxide and superoxide dismutase modulate endothelial progenitor cell function in type 2 diabetes mellitus

2009

Benjamin Brenner, MD
Authors : Hamed S, Brenner B, Aharon A, Daoud D, Roguin A.

Cardiovasc Diabetol. 2009 Oct 30;8:56

Urinary Excretion of Endothelin Receptors ET(A) and ET(B) in Hypertensive Patients and Normotensive Subjects

2009

Aaron Hoffman, MD
Authors : Karram T, Khamaisi M, Bishara B, Ramadan R, Nitecki S, Ben-Izhak O, Meretyk S, Winaver J, Heyman SN, Hoffman A, Abassi Z.

Kidney Blood Press Res. 2009 32(4):293-303.

Cardiomyocyte Differentiation of Human Induced Pluripotent Stem Cells

2009

Lior Gepstein, MD, PhD
Authors : Zwi L, Caspi O, Arbel G, Huber I, Gepstein A, Park IH, Gepstein L.

Circulation. 2009 Sep 28. [Epub ahead of print]

Lipoprotein interactions with chromatic membranes as a novel marker for oxidative stress – related diseases

2009

Michael Aviram, DSc
Authors : Hanin-Avraham N, Fuhrman B, Mech-Dorosz A, Kolusheva S, Porgador A, Aviram M, Jelinek R.

Biochim Biophys Acta. 2009 Sep 28. [Epub ahead of print]

Divergent effects of alpha-tocopherol and vitamin C on the generation of dysfunctional HDL associated with Diabetes and the Hp 2-2 genotype

2009

Andrew Levy, MD, PhD
Authors : Asleh R, Levy A.

Antioxid Redox Signal. 2009 Sep 21. [Epub ahead of print]

Pomegranate juice polyphenols increase recombinant paraoxonase-1 binding to high-density lipoprotein: Studies in vitro and in diabetic patients

2009

Michael Aviram, DSc
Authors : Fuhrman B, Volkova N, Aviram M.

Nutrition. 2009 Sep 15. [Epub ahead of print]

Effects of date (Phoenix dactylifera L., Medjool or Hallawi Variety) consumption by healthy subjects on serum glucose and lipid levels and on serum oxidative status: a pilot study

2009

Michael Aviram, DSc
Authors : Rock W, Rosenblat M, Borochov-Neori H, Volkova N, Judeinstein S, Elias M, Aviram M.

J Agric Food Chem. 2009 Sep 9;57(17):8010-7.

Paraoxonase 1(PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: A role for PPAR-gamma pathway

2009

Michael Aviram, DSc
Authors : Khateeb J, Gantman A, Kreitenberg AJ, Aviram M, Fuhrman B.

Atherosclerosis. 2009 Sep 6. [Epub ahead of print]

The haptoglobin 2-2 genotype is associated with increased redox active hemoglobin derived iron in the atherosclerotic plaque.

2009

Andrew Levy, MD, PhD
Authors : Kalet-Litman S, Moreno PR, Levy AP.

Atherosclerosis. 2009 Sep 6. [Epub ahead of print]

Paraoxonase 2 (PON2) decreases high glucose-induced macrophage triglycerides (TG) accumulation, via inhibition of NADPH-oxidase and DGAT1 activity: Studies in PON2-deficient mice

2009

Michael Aviram, DSc
Authors : Meilin E, Aviram M, Hayek T.

Atherosclerosis. 2009 Aug 8. [Epub ahead of print]

Haptoglobin :basic and clinical aspects

2009

Andrew Levy, MD, PhD
Authors : Levy A, Asleh R, Blum S, Levy N, Miller-Lotan R, Kalet-Litman S, Anbinder Y, Lache O, Nakhoul F, Asaf R, Farbstein D, Pollak M, Soloveichik Y, Strauss M, Alshiek J, Livshits A, Schwartz A, Awad H, Jad K, Goldenstein H.

Antioxid Redox Signal. 2009 Aug 6

Transplantation of a Tissue-Engineered Human Vascularized Cardiac Muscle

2009

Lior Gepstein, MD, PhD
Authors : Lesman A, Habib M, Caspi O, Gepstein A, Arbel G, Levenberg S, Gepstein L.

Tissue Eng Part A. 2009 Jul 30

Assessment and management of high-risk pregnancies in women with thrombophilia

2009

Benjamin Brenner, MD
Authors : Sarig G, Vidergor G, Brenner B.

Blood Rev. 2009 Jul;23(4):143-7

Urokinase activates macrophage PON2 gene transcription via the PI3K/ROS/MEK/SREBP-2 signaling cascade mediated by the PDGFR-{beta}

2009

Michael Aviram, DSc
Authors : Fuhrman B, Gantman A, Khateeb J, Volkova N, Horke S, Kiyan J, Dumler I, Aviram M.

Cardiovasc Res. 2009 Jun 4.

Haptoglobin genotype is a determinant of survival and cardiac remodeling after myocardial infarction in diabetic mice

2009

Andrew Levy, MD, PhD
Authors : Asaf R, Blum S, Roguin A, Kalet-Litman S, Kheir J, Frisch A, Miller-Lotan R,

Cardiovasc Diabetol. 2009 Jun 2;8:29.

Vitamin K-dependent coagulation factors deficiency

2009

Benjamin Brenner, MD
Authors : Brenner B, Kuperman AA, Watzka M, Oldenburg J.

Semin Thromb Hemost. 2009 Jun;35(4):439-46

Antioxidants in the prevention of Atherosclerosis: The importance of proper patient selection

2009

Andrew Levy, MD, PhD
Authors : Levy Y, Blum S, Levy AP.

Clin Nutr. 2009 May 21.

Paraoxonase 2 attenuates macrophage triglyceride accumulation via inhibition of diacylglycerol acyltransferase 1

2009

Michael Aviram, DSc
Authors : Rosenblat M, Coleman R, Reddy ST, Aviram M.

J Lipid Res.2009, 50(5):870-9

Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus

2009

Andrew Levy, MD, PhD
Authors : Nakhoul FM, Miller-Lotan R, Awad H, Asleh R, Jad K, Nakhoul N, Asaf R, Abu-Saleh N, Levy AP.

Am J Physiol Renal Physiol. 2009 Apr; 296(4):F830-8.

Shear stress-induced transcriptional regulation via hybrid promoters as a potential tool for promoting angiogenesis

2009

Ofer Binah, PhD
Authors : Silberman M, Barac YD, Yahav H, Wolfovitz E, Einav S, Resnick N, Binah O.

Angiogenesis. 2009 Mar 26. [Epub ahead of print]

Cancer and thrombosis

2009

Benjamin Brenner, MD
Authors : Brenner B.

Best Pract Res Clin Haematol. 2009 Mar;22(1):1-2.

Heparanase coagulation and cancer progression

2009

Benjamin Brenner, MD
Authors : Nadir Y, Brenner B.

Best Pract Res Clin Haematol. 2009 Mar;22(1):85-92. Review

Microparticles, thrombosis and cancer

2009

Benjamin Brenner, MD
Authors : Aharon A, Brenner B.

Best Pract Res Clin Haematol. 2009 Mar;22(1):61-9. Review

Tissue factor- and tissue factor pathway inhibitor-bearing microparticles in gestational vascular complications

2009

Benjamin Brenner, MD
Authors : A, Katzenell S, Tamari T, Brenner B.

J Thromb Haemost. 2009 Mar 13. [Epub ahead of print]

Human carotid atherosclerotic plaque increases oxidative state of macrophages and low-density lipoproteins‭, ‬whereas paraoxonase 1‭ (‬PON1‭) ‬decreases such atherogenic effects

2009

Michael Aviram, DSc
Authors : Tavori H‭, ‬Aviram M‭, ‬Khatib S‭, ‬Musa R‭, ‬Nitecki S‭, ‬Hoffman A‭, ‬Vaya J‭. ‬

Free Radic Biol Med‭. ‬2009‭ ‬Mar 1‭;‬46‭(‬5‭):‬607-15‭.

Impulse conduction and gap junctional remodelling by endothelin-1 in cultured neonatal rat ventricular myocytes

2009

Ofer Binah, PhD
Authors : Reisner Y, Meiry G, Zeevi-Levin N, Barac DY, Reiter I, Abassi Z, Ziv N, Kostin S, Schaper J, Rosen MR, Binah O.

J Cell Mol Med. 2009 Mar;13(3):562-73. PubMed PMID: 19374685.

Lipid profile and serum characteristics of the blind subterranean mole rat, Spalax

2009

Michael Aviram, DSc
Authors : Nasser NJ, Kaplan M, Nevo E, Aviram M.

PLoS ONE. 2009;4(2):e4528.

A photopolymerizable hydrogel for 3-D culture of human embryonic stem cell-derived cardiomyocytes and rat neonatal cardiac cells

2009

Lior Gepstein, MD, PhD
Authors : Shapira-Schweitzer K, Habib M, Gepstein L, Seliktar D.

J Mol Cell Cardiol. 2009 Feb;46(2):213-24.

Di-oleoyl phosphatidylcholine (PC-18:1) stimulates paraoxonase 1 (PON1) enzymatic and biological activities: in vitro and in vivo studies

2009

Michael Aviram, DSc
Authors : Efrat M, Rosenblat M, Mahmood S, Vaya J, Aviram M.

Atherosclerosis. 2009; 202(2):461-9.

Corpus luteum hemorrhage in women with bleeding disorders

2009

Benjamin Brenner, MD
Authors : Hoffman R, Brenner B.

Womens Health (Lond Engl). 2009 Jan;5(1):91-5

Paraoxonases role in the prevention of cardiovascular diseases

2009

Michael Aviram, DSc
Authors : Rosenblat M, Aviram M.

Biofactors. 2009;35(1):98-104.

Paraoxonases role in the prevention of cardiovascular diseases

2009

Michael Aviram, DSc
Authors : Rosenblat M, Aviram M.

Biofactors. 2009 Jan-Feb;35(1):98-104.

Prophylaxis of travel-related thrombosis in women

2009

Benjamin Brenner, MD
Authors : Brenner B.

Thromb Res. 2009;123 Suppl 3:S26-9.

Best Pract Res Clin Haematol.

2009

Benjamin Brenner, MD
Authors : Aharon A, Brenner B. Microparticles, thrombosis and cancer.

22, 61-9.

Cardiomyocyte differentiation of human induced pluripotents stem cells

2009

Lior Gepstein, MD, PhD
Authors : Zwi L, Caspi O, Arbel G, Huber I, Gepstein A, Park IH, Gepstein L.

Circulation. 120, 1513-1523.

Microparticles and placental hemostasis

2009

Benjamin Brenner, MD
Authors : Aharon A, Brenner B.

Thromb Res. 2009;123 Suppl 2:S88-92.

Macrophage paraoxonase 1 (PON1) binding sites

2008

Michael Aviram, DSc
Authors : Efrat M, Aviram M.

Biochem Biophys Res Commun. 2008 Nov 7;376(1):105-10. Epub 2008 Aug 30

Monocyte-derived microparticles and exosomes induce procoagulant and apoptotic effects on endothelial cells

2008

Benjamin Brenner, MD
Authors : Aharon A, Tamari T, Brenner B.

Thromb Haemost. 2008 Nov;100(5):878-85

Phenolic antioxidants and antiatherogenic effects of Marula (Sclerocarrya birrea Subsp. caffra) fruit juice in healthy humans

2008

Michael Aviram, DSc
Authors : Borochov-Neori H, Judeinstein S, Greenberg A, Fuhrman B, Attias J, Volkova N, Hayek T, Aviram M.

J Agric Food Chem. 2008 Nov 12;56(21):9884-91. Epub 2008 Oct 10

Correction of HDL dysfunction in individuals with diabetes and the haptoglobin 2-2 genotype

2008

Andrew Levy, MD, PhD
Authors : Asleh R, Blum S, Kalet-Litman S, Alshiek J, Miller-Lotan R, Asaf R, Rock W, Aviram M, Milman U, Shapira C, Abassi Z, Levy AP.

Diabetes. 2008 Oct;57(10):2794-800. Epub 2008 Jul 3

Mechanical load induced by glass microspheres releases angiogenic factors from neonatal rat ventricular myocytes cultures and causes arrhythmias

2008

Ofer Binah, PhD
Authors : Barac DY, Reisner Y, Silberman M, Zeevi-Levin N, Danon A, Salomon O, Shoham M, Shilkrut M, Kostin S, Schaper J, Binah O

J Cell Mol Med. 2008 Oct;12(5B):2037-51

Regulation of CD163 associated casein kinase II activity is haptoglobin genotype dependent

2008

Andrew Levy, MD, PhD
Authors : Strauss M, Levy AP.

Mol Cell Biochem. 2008 Oct;317(1-2):131-5. Epub 2008 Jun 19

1,4,5-Inositol Trisphosphate Operated [Ca2+]i Stores And Angiotensin-II/Endothelin-1 Signaling Pathway Are Functional In Human Embryonic Stem Cell-Derived Cardiomyocytes

2008

Ofer Binah, PhD
Authors : Sedan O, Dolnikov K, Zeevi-Levine N, Fleishmann N, Amit M, Itskovitz-Eldor J, Binah O

Stem Cells. 2008 Sep 25. [Epub ahead of print]

Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities

2008

Andrew Levy, MD, PhD | Michael Aviram, DSc
Authors : Rock W, Rosenblat M, Miller-Lotan R, Levy AP, Elias M, Aviram M.

J Agric Food Chem. 2008 Sep 24;56(18):8704-13. Epub 2008 Aug 30

TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity

2008

Ofer Binah, PhD
Authors : Kleiner Y, Bar-Am O, Amit T, Berdichevski A, Liani E, Maor G, Reiter I, Youdim MB, Binah O

J Cardiovasc Pharmacol. 2008 Sep;52(3):268-77

Heparanase, tissue factor, and cancer

2008

Benjamin Brenner, MD
Authors : Nadir Y, Vlodavsky I, Brenner B.

Semin Thromb Hemost. 2008 Mar;34(2):187-94. PMID: 18645924

Abstract

Antiatherogenicity of extra virgin olive oil and its enrichment with green tea polyphenols in the atherosclerotic apolipoprotein-E-deficient mice: enhanced macrophage cholesterol efflux

2008

Michael Aviram, DSc
Authors : Rosenblat M, Volkova N, Coleman R, Almagor Y, Aviram M.

J Nutr Biochem. 2008 Aug;19(8):514-23. Epub 2007 Sep 27

Calcium handling in human embryonic stem cell-derived cardiomyocytes

2008

Lior Gepstein, MD, PhD
Authors : Satin J, Itzhaki I, Rapoport S, Schroder EA, Izu L, Arbel G, Beyar R, Balke CW, Schiller J, Gepstein L.

Stem Cells. 2008 Aug;26(8):1961-72. Epub 2008 May 15

Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism

2008

Michael Aviram, DSc
Authors : Fuhrman B, Khateeb J, Shiner M, Nitzan O, Karry R, Volkova N, Aviram M.

Arterioscler Thromb Vasc Biol. 2008 Jul;28(7):1361-7. Epub 2008 Apr 24

Controlling Ischemic Cardiovascular Disease: From Basic Mechanisms to Clinical Management.

2008

Rafael Beyar, MD, DSc
Authors : Beyar R.

Ann N Y Acad Sci. 2008 Mar;1123:232-236. PMID: 18375595 [PubMed – as supplied by publisher]

Drug-eluting versus bare-metal stents: when and for whom?

2008

Rafael Beyar, MD, DSc
Authors : Nikolsky E.

J Invasive Cardiol. 2008 Mar;20(3):105-6. No abstract available. PMID: 18316824 [PubMed – in process]

Dual therapy with statins and antioxidants is superior to statins alone in decreasing the risk of cardiovascular disease in a subgroup of middle-aged individuals with both diabetes mellitus and the haptoglobin 2-2 genotype.

2008

Andrew Levy, MD, PhD
Authors : Blum S, Milman U, Shapira C, Miller-Lotan R, Bennett L, Kostenko M, Landau M, Keidar S, Levy Y, Khemlin A, Radan A

Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):e18-20.

Experimental Molecular and Stem Cell Therapies in Cardiac Electrophysiology

2008

Lior Gepstein, MD, PhD
Authors :

Ann N Y Acad Sci. 2008 Mar;1123:224-231.

Troponin-positive, CK-MB-negative acute myocardial infarction: clinical, electrocardiographic and angiographic characteristics.

2008

Rafael Beyar, MD, DSc
Authors : Gruberg L, Sudarsky D, Kerner A, Hammerman H, Kapeliovich M

J Invasive Cardiol. 2008 Mar;20(3):125-8. PMID: 18316828 [PubMed – in process]

Cell therapy for modification of the myocardial electrophysiological substrate.

2008

Lior Gepstein, MD, PhD
Authors : Yankelson L, Feld Y, Bressler-Stramer T, Itzhaki I, Huber I, Gepstein A, Aronson D, Marom S

Circulation. 2008 Feb 12;117(6):720-31.

Heart inefficiency in pulmonary hypertension: a double jeopardy

2008

Rafael Beyar, MD, DSc
Authors :

J Am Coll Cardiol. 2008 Feb 19;51(7):758-9. No abstract available.

Ox-LDL induces monocyte-to-macrophage differentiation in vivo: Possible role for the macrophage colony stimulating factor receptor (M-CSF-R).

2008

Michael Aviram, DSc
Authors : Fuhrman B, Partoush A, Volkova N

Atherosclerosis. 2008 Feb;196(2):598-607.

Pomegranate phenolics from the peels, arils, and flowers are antiatherogenic:studies in vivo in atherosclerotic apolipoprotein e-deficient (E 0) mice and in vitro

2008

Michael Aviram, DSc
Authors : Volkova N, Coleman R, Dreher M, Reddy MK, Ferreira D, Rosenblat M.

J Agric Food Chem. 2008 Feb 13;56(3):1148-57.

Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial.

2008

Andrew Levy, MD, PhD
Authors : Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, Alshiek J, Bennett L, Kostenko M, Landau M, Keidar S, Levy Y, Khemlin A, Radan A.

Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):341-7.

Acute coronary syndrome revisited – markers, interventions and complications.

2008

Rafael Beyar, MD, DSc
Authors :

Acute Card Care. 2008;10(1):3-4.

Thrombophilia and adverse pregnancy outcome.

2007

Benjamin Brenner, MD
Authors : Aharon A.

Clin Perinatol. 2007 Dec;34(4):527-41

Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E.

2007

Andrew Levy, MD, PhD
Authors : Blum S.

Expert Rev Cardiovasc Ther. 2007 Nov;5(6):1105-11. Review.

Electrophysiological coupling of transplanted cardiomyocytes.

2007

Lior Gepstein, MD, PhD
Authors : Kehat I.

Circ Res. 2007 Aug 31;101(5):433-5

Hyperlipidaemia and cardiovascular disease.

2007

Michael Aviram, DSc
Authors :

Curr Opin Lipidol. 2007 Aug;18(4):473-5.

Downregulation of the hemoglobin scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability.

2007

Andrew Levy, MD, PhD
Authors : Purushothaman KR, Levy NS, Purushothaman M, Strauss M, Asleh R, Marsh S, Cohen O, Moestrup SK, Moller HJ, Zias EA, Benhayon D, Fuster V, Moreno PR.

Circ Res. 2007 Jul 6;101(1):106-10.

Plasma serotonin levels and the platelet serotonin transporter.

2007

Benjamin Brenner, MD
Authors : Harney JT, Ahmed BA, Jeffus BC, Unal R, Mehta JL, Kilic F.

J Neurochem. 2007 Jul;102(1):206-15.

Haptoglobin 1-1 genotype and the risk of life-threatening streptococcus infection: Evolutionary implications.

2007

Andrew Levy, MD, PhD
Authors : Wasserzug O, Blum S, Klement E, Lejbkowicz F, Miller-Lotan R, Levy AP.

Infect. 2007;54(4):410.

Hypothesis–haptoglobin genotype and diabetic nephropathy.

2007

Andrew Levy, MD, PhD
Authors : Nakhoul FM, Miller-Lotan R, Awaad H, Asleh R.

Nat Clin Pract Nephrol. 2007 Jun;3(6):339-44

Read the Article

Consumption of a novel dietary formula of plant sterol esters of canola oil Fatty acids, in a canola oil matrix containing 1,3-diacylglycerol, reduces oxidative stress in atherosclerotic apolipoprotein e-deficient mice.

2007

Michael Aviram, DSc | Andrew Levy, MD, PhD
Authors : Fuhrman B, Plat D, Herzog Y.

J Agric Food Chem. 2007 Mar 7;55(5):2028-33.

Read the Article:

Haptoglobin genotype modulates the balance of Th1/Th2 cytokines produced by macrophages exposed to free hemoglobin.

2007

Atherosclerosis. 2007 Mar;191(1):48-53.

Retinal capillary basement membrane thickness in diabetic mice genetically modified at the haptoglobin locus.

2007

Andrew Levy, MD, PhD
Authors : Miller-Lotan R, Miller B, Nakhoul F, Aronson D, Asaf R, Levy AP.

2007;23(2):152-6.

Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.

2007

Benjamin Brenner, MD
Authors : Wiis J.

Hematology. 2007 Feb;12(1):55-62

Read the Aarticle

Biomarkers, imaging and interventions–going up hill.

2007

Rafael Beyar, MD, DSc
Authors :

Acute Card Care. 2007;9(4):195-6.

Haptoglobin genotype determines myocardial infarct size in diabetic mice.

2007

Andrew Levy, MD, PhD
Authors : Blum S, Asaf R, Guetta J, Miller-Lotan R, Asleh R, Kremer R, Levy NS, Berger FG, Aronson D, Fu X, Zhang R, Hazen SL, Levy AP.

J Am Coll Cardiol. 2007 Jan 2;49(1):82-7.

Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque.

2007

Andrew Levy, MD, PhD
Authors : Levy AP, Levy JE, Kalet-Litman S, Miller-Lotan R, Levy NS, Asaf R, Guetta J, Yang C, Purushothaman KR, Fuster V, Moreno PR.

Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):134-40.

Markers, lumenology and beyond- focus on acute heart failure and acute coronary conditions.

2007

Rafael Beyar, MD, DSc
Authors :

Acute Card Care. 2007;9(1):4-5

Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo.

2006

Andrew Levy, MD, PhD
Authors : Asleh R, Miller-Lotan R, Aviram M, Hayek T, Yulish M, Levy JE, Miller B, Blum S, Milman U, Shapira C, Levy AP.

Circ Res. 2006 Dec 8;99(12):1419-25.

Myocardial regeneration strategies using human embryonic stem cell-derived cardiomyocytes.

2006

Lior Gepstein, MD, PhD
Authors : Capi O.

J Control Release. 2006 Nov 28;116(2):211-8.

Read the Article

Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy.

2006

Pharmacol Ther. 2006 Nov;112(2):501-12.

Read the Article:

Evaluation of ProC Global assay in women with a history of venous thromboembolism on hormonal therapy.

2006

Benjamin Brenner, MD
Authors : Sarig G, Aberbach I, Schliamser L, Blumenfeld Z, Brenner B.

Thromb Haemost. 2006 Nov;96(5):578-83.

Interventions to prevent venous thrombosis after air travel, are they necessary? Yes.

2006

Benjamin Brenner, MD
Authors : Brenner B.

J Thromb Haemost. 2006 Nov;4(11):2302-5.

The 192R/Q polymorphs of serum paraoxonase PON1 differ in HDL binding, lipolactonase stimulation, and cholesterol efflux.

2006

Michael Aviram, DSc
Authors : Gaidukov L, Rosenblat M, Aviram M, Tawfik DS.

J Lipid Res. 2006 Nov;47(11):2492-502. Epub 2006 Aug 16. PMID: 16914770 [PubMed – indexed for MEDLINE]

S-Glutathionylation regulates HDL-associated paraoxonase 1 (PON1) activity.

2006

Michael Aviram, DSc
Authors : Rozenberg O, Aviram M.

Biochem Biophys Res Commun. 2006 Oct 18;351(2):492-498

Calcium handling in embryonic stem cell-derived cardiac myocytes: of mice and men.

2006

Lior Gepstein, MD, PhD
Authors : Itzhaki I, Schiller J, Beyar R, Satin J,

Ann N Y Acad Sci. 2006 Oct;1080:207-15.

Cardiovascular therapeutic aspects of cell therapy and stem cells.

2006

Lior Gepstein, MD, PhD
Authors :

Ann N Y Acad Sci. 2006 Oct;1080:415-25.

Five-year clinical follow up after intracoronary radiation for the prevention of in-stent restenosis.

2006

Rafael Beyar, MD, DSc
Authors : Gruberg L, Caiati R, Aronson D, Suleiman M, Petchersky S, Nikolsky E, Grenadier E, Boulus M, Markiewicz W, Kerner A, Beyar R.

J Invasive Cardiol. 2006 Oct;18(10):494-8.

Prevalence of Upper Extremity Deep Venous Thrombosis Diagnosed by Color Doppler Duplex Sonography in Cancer Patients With Central Venous Catheters.

2006

Benjamin Brenner, MD
Authors : Gaitini D, Beck-Razi N, Haim N, Brenner B.

J Ultrasound Med. 2006 Oct;25(10):1297-1303.

End-stage renal disease and drug-eluting stents: one small step forward.

2006

Rafael Beyar, MD, DSc
Authors : Gruberg L, Beyar R.

J Invasive Cardiol. 2006 Sep;18(9):409-10.

From gene therapy and stem cells to clinical electrophysiology.

2006

Lior Gepstein, MD, PhD
Authors : Yankelson L,Gepstein L.

Pacing Clin Electrophysiol. 2006 Sep;29(9):996-1005.

Pomegranate juice shows possible diabetes benefits

2006

Michael Aviram, DSc
Authors : Stephen Daniells and Michael Aviram

Pharmacological prevention of venous thromboembolism before air travel. Is it necessary? Yes.

2006

Benjamin Brenner, MD
Authors : Brenner B.

J Thromb Haemost. 2006 Aug 23; [Epub ahead of print] No abstract available. PMID: 16938123 [PubMed – as supplied by publisher]

Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: Relevance to diabetes.

2006

Michael Aviram, DSc
Authors : Rosenblat M, Karry R, Aviram M.

Atherosclerosis. 2006 Jul;187(1):74-81. Epub 2005 Oct 17. PMID: 16229851 [PubMed – in process]

Postprandial serum triacylglycerols and oxidative stress in mice after consumption of fish oil, soy oil or olive oil: Possible role for paraoxonase-1 (PON1) triacylglycerol lipase-like activity.

2006

Michael Aviram, DSc
Authors : Fuhrman B, Volkova N, Aviram M.

Nutrition. 2006 Jun 29; [Epub ahead of print] PMID: 16814984 [PubMed – as supplied by publisher]

Lysophosphatidylcholine (LPC) attenuates macrophage-mediated oxidation of LDL.

2006

Michael Aviram, DSc
Authors : Rosenblat M, Oren R, Aviram M.

Biochem Biophys Res Commun. 2006 Jun 16;344(4):1271-7.

A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages.

2006

Benjamin Brenner, MD
Authors : Dolitzky M, Inbal A, Segal Y, Weiss A, Brenner B, Carp H.

Fertil Steril. 2006 Jun 9; [Epub ahead of print] PMID: 16769056 [PubMed – as supplied by publisher]

Preprocedural C-reactive protein levels predict myocardial necrosis after successful coronary stenting in patients with stable angina.

2006

Rafael Beyar, MD, DSc
Authors : Goldberg A, Gruberg L, Roguin A, Petcherski S, Rimer D, Markiewicz W, Beyar R, Aronson D.

Am Heart J. 2006 Jun;151(6):1265-70. PMID: 16781234 [PubMed – in process]

Neovascularization in human atherosclerosis.

2006

Andrew Levy, MD, PhD
Authors : Moreno PR, Purushothaman KR, Sirol M, Levy AP, Fuster V.

Circulation. 2006 May 9;113(18):2245-52. Review.

Duplex Ultrasound Verified by Angiography in Patients with Severe Primary and Restenosis of Internal Carotid Artery.

2006

Rafael Beyar, MD, DSc
Authors : Telman G, Kouperberg E, Sprecher E, Gruberg L, Beyar R, Hoffman A, Yarnitsky D.

Ann Vasc Surg. 2006 Apr 27; [Epub ahead of print] PMID: 16642286 [PubMed – as supplied by publisher]

Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction.

2006

Rafael Beyar, MD, DSc
Authors : Goldberg A, Hammerman H, Petcherski S, Nassar M, Zdorovyak A, Yalonetsky S, Kapeliovich M, Agmon Y, Beyar R, Markiewicz W, Aronson D.

Arch Intern Med. 2006 Apr 10;166(7):781-6. PMID: 16606816 [PubMed – indexed for MEDLINE]

Acute cardiac care: apocalypse now!

2006

Rafael Beyar, MD, DSc
Authors : Beyar R, Filippatos G, Gheorghiade M, Tamai H, Galvani M, Hasin Y, Keren G, Leon MB.

Acute Card Care. 2006 Apr;8(1):4-6. No abstract available. PMID: 16720420 [PubMed – in process]

Carotid artery stenting in surgical high-risk patients.

2006

Rafael Beyar, MD, DSc
Authors : Halabi M, Gruberg L, Pitchersky S, Kouperberg E, Nikolsky E, Hoffman A, Beyar R.

Catheter Cardiovasc Interv. 2006 Apr;67(4):513-8. PMID: 16534816 [PubMed – in process]

Multicenter evaluation of a self-expanding carotid stent system with distal protection in the treatment of carotid stenosis.

2006

Rafael Beyar, MD, DSc
Authors : Hill MD, Morrish W, Soulez G, Nevelsteen A, Maleux G, Rogers C, Hauptmann KE, Bonafe A, Beyar R, Gruberg L, Schofer J; MAVErlC International Investigators.

AJNR Am J Neuroradiol. 2006 Apr;27(4):759-65. PMID: 16611760 [PubMed – in process]

The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux.

2006

Michael Aviram, DSc
Authors : Rosenblat M, Gaidukov L, Khersonsky O, Vaya J, Oren R, Tawfik DS, Aviram M.

J Biol Chem. 2006 Mar 17;281(11):7657-65. Epub 2006 Jan 10. PMID: 16407304 [PubMed – indexed for MEDLINE]

Pomegranate byproduct administration to apolipoprotein e-deficient mice attenuates atherosclerosis development as a result of decreased macrophage oxidative stress

2006

Michael Aviram, DSc
Authors : Rosenblat M, Volkova N, Coleman R, Aviram M.

J Agric Food Chem. 2006 Mar 8;54(5):1928-35. PMID: 16506855 [PubMed – indexed for MEDLINE]

Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein.

2006

Rafael Beyar, MD, DSc
Authors : Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M, Levy Y, Beyar R, Markiewicz W, Hammerman H, Aronson D.

J Am Coll Cardiol. 2006 Mar 7;47(5):962-8. PMID: 16516078 [PubMed – indexed for MEDLINE]

Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin.

2006

Benjamin Brenner, MD
Authors : Nasser NJ, Sarig G, Brenner B, Nevo E, Goldshmidt O, Zcharia E, Li JP, Vlodavsky I.

J Thromb Haemost. 2006 Mar;4(3):560-5. PMID: 16460439 [PubMed – indexed for MEDLINE]

Regenerating the heart using human embryonic stem cells–from cell to bedside.

2006

Lior Gepstein, MD, PhD
Authors : Caspi O, Gepstein L.

Isr Med Assoc J. 2006 Mar;8(3):208-14. Review. PMID: 16599061 [PubMed – indexed for MEDLINE]

Functional properties of human embryonic stem cell-derived cardiomyocytes: intracellular Ca2+ handling and the role of sarcoplasmic reticulum in the contraction.

2006

Ofer Binah, PhD
Authors : Dolnikov K, Shilkrut M, Zeevi-Levin N, Gerecht-Nir S, Amit M, Danon A, Itskovitz-Eldor J, Binah O.

Stem Cells. 2006 Feb;24(2):236-45.

Glycoprotein IIb/IIIa inhibitors during rescue percutaneous coronary intervention in acute myocardial infarction.

2006

Rafael Beyar, MD, DSc
Authors : Gruberg L, Suleiman M, Kapeliovich M, Hammerman H, Grenadier E, Boulus M, Amikam S, Markiewicz W, Beyar R.

J Invasive Cardiol. 2006 Feb;18(2):59-62. PMID: 16446517 [PubMed – indexed for MEDLINE]

Remote-control percutaneous coronary interventions: concept, validation, and first-in-humans pilot clinical trial.

2006

Rafael Beyar, MD, DSc
Authors : Beyar R, Gruberg L, Deleanu D, Roguin A, Almagor Y, Cohen S, Kumar G, Wenderow T.

J Am Coll Cardiol. 2006 Jan 17;47(2):296-300. Epub 2006 Jan 4. PMID: 16412850 [PubMed – indexed for MEDLINE]

16-MDCT coronary angiography versus invasive coronary angiography in acute chest pain syndrome: a blinded prospective study.

2006

Rafael Beyar, MD, DSc
Authors : Ghersin E, Litmanovich D, Dragu R, Rispler S, Lessick J, Ofer A, Brook OR, Gruberg L, Beyar R, Engel A.

AJR Am J Roentgenol. 2006 Jan;186(1):177-84. PMID: 16357399 [PubMed – indexed for MEDLINE]

A mouse model for human atherosclerosis: long-term histopathological study of lesion development in the aortic arch of apolipoprotein E-deficient (E0) mice.

2006

Michael Aviram, DSc
Authors : Coleman R, Hayek T, Keidar S, Aviram M.

Acta Histochem. 2006;108(6):415-24. Epub 2006 Sep 26. Review. PMID: 17007910 [PubMed – indexed for MEDLINE]

Acute Cardiac Care: the lifting of the veil.

2006

Rafael Beyar, MD, DSc
Authors : Beyar R, Filippatos G.

Acute Card Care. 2006;8(3):131-2.

Contrast enhanced multi-detector computed tomography coronary angiography versus conventional invasive quantitative coronary angiography in acute coronary syndrome patients-correlation and bias.

2006

Rafael Beyar, MD, DSc
Authors : Dragu R, Rispler S, Ghersin E, Gruberg L, Lessick J, Litmanovich D, Aronson D, Hammerman H, Ofer A, Engel A, Beyar R.

Acute Card Care. 2006;8(2):99-104. PMID: 16885074 [PubMed – in process]

Effect of a Mediterranean meal on postprandial carotenoids, paraoxonase activity and C-reactive protein levels.

2006

Michael Aviram, DSc
Authors : Blum S, Aviram M, Ben-Amotz A, Levy Y.

Ann Nutr Metab. 2006;50(1):20-4. Epub 2005 Nov 4. PMID: 16276071 [PubMed – indexed for MEDLINE]

Exogenous N-linoleoyl tyrosine marker as a tool for the characterization of cellular oxidative stress in macrophages.

2006

Michael Aviram, DSc
Authors : Szuchman A, Aviram M, Soliman K, Tamir S, Vaya J.

Free Radic Res. 2006 Jan;40(1):41-52. PMID: 16298758 [PubMed – indexed for MEDLINE]

Haptoglobin phenotypes, which one is better and when?

2006

Andrew Levy, MD, PhD
Authors : Zvi B, Levy AP.

Clin Lab. 2006;52(1-2):29-35.

The eccentric lumenology.

2006

Rafael Beyar, MD, DSc
Authors : Nair P, Gruberg L, Beyar R.

Acute Card Care. 2006;8(2):87-94.

Thrombophilia and pregnancy complications.

2006

Benjamin Brenner, MD
Authors : Brenner B.

Pathophysiol Haemost Thromb. 2006;35(1-2):28-35.

Pomegranate juice sugar fraction reduces macrophage oxidative state, whereas white grape juice sugar fraction increases it.

2005

Michael Aviram, DSc
Authors : Rozenberg O, Howell A, Aviram M.

Atherosclerosis. 2005 Dec 2; [Epub ahead of print] PMID: 16332370 [PubMed – as supplied by publisher]

Endoluminal hydrogel films made of alginate and polyethylene glycol: physical characteristics and drug-eluting properties.

2005

Rafael Beyar, MD, DSc
Authors : Livnat M, Beyar R, Seliktar D.

J Biomed Mater Res A. 2005 Dec 1;75(3):710-22. PMID: 16100722 [PubMed – indexed for MEDLINE]

Stem cells as biological heart pacemakers.

2005

Lior Gepstein, MD, PhD
Authors : Gepstein L.

Expert Opin Biol Ther. 2005 Dec;5(12):1531-7. Review. PMID: 16318417 [PubMed – indexed for MEDLINE]

Coronary perforation 2006 – watch for the wire.

2005

Rafael Beyar, MD, DSc
Authors : Roguin A, Beyar R.

J Invasive Cardiol. 2005 Nov;17(11):606-8. No abstract available. PMID: 16264207 [PubMed – indexed for MEDLINE]

Hemostatic balance on the surface of leukemic cells: the role of tissue factor and urokinase plasminogen activator receptor.

2005

Benjamin Brenner, MD
Authors : Nadir Y, Katz T, Sarig G, Hoffman R, Oliven A, Rowe JM, Brenner B.

Haematologica. 2005 Nov;90(11):1549-56. PMID: 16266903 [PubMed – in process]

Macrophage foam-cell formation in streptozotocin-induced diabetic mice: stimulatory effect of glucose.

2005

Michael Aviram, DSc
Authors : Hayek T, Hussein K, Aviram M, Coleman R, Keidar S, Pavoltzky E, Kaplan M.

Atherosclerosis. 2005 Nov;183(1):25-33. Epub 2005 Apr 1. PMID: 16216589 [PubMed – indexed for MEDLINE]

Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss.

2005

Benjamin Brenner, MD
Authors : Sarig G, Blumenfeld Z, Leiba R, Lanir N, Brenner B.

Thromb Haemost. 2005 Nov;94(5):980-5. PMID: 16363240 [PubMed – indexed for MEDLINE]

Hydrogen peroxide predisposes neonatal rat ventricular myocytes to Fas-mediated apoptosis.

2005

Ofer Binah, PhD
Authors : Yaniv G, Shilkrut M, Larisch S, Binah O.

Biochem Biophys Res Commun. 2005 Oct 28;336(3):740-6. PMID: 16157298 [PubMed – indexed for MEDLINE]

Anti-oxidative effects of pomegranate juice (PJ) consumption by diabetic patients on serum and on macrophages.

2005

Michael Aviram, DSc
Authors : Rosenblat M, Hayek T, Aviram M.

Atherosclerosis. 2005 Oct 11; [Epub ahead of print] PMID: 16226266 [PubMed – as supplied by publisher]

The 1,4,5-inositol trisphosphate pathway is a key component in Fas-mediated hypertrophy in neonatal rat ventricular myocytes.

2005

Ofer Binah, PhD
Authors : Barac YD, Zeevi-Levin N, Yaniv G, Reiter I, Milman F, Shilkrut M, Coleman R, Abassi Z, Binah O.

Cardiovasc Res. 2005 Oct 1;68(1):75-86. PMID: 16005448 [PubMed – indexed for MEDLINE]

Pomegranate juice inhibits oxidized LDL uptake and cholesterol biosynthesis in macrophages.

2005

Michael Aviram, DSc
Authors : Fuhrman B, Volkova N, Aviram M.

J Nutr Biochem. 2005 Sep;16(9):570-6. PMID: 16115546 [PubMed – indexed for MEDLINE]

Increased blood vessel density provides the mole rat physiological tolerance to its hypoxic subterranean habitat.

2005

Andrew Levy, MD, PhD
Authors : Avivi A, Shams I, Joel A, Lache O, Levy AP, Nevo E.

FASEB J. 2005 Aug;19(10):1314-6.

Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: selective secretion of PON1 and PON2.

2005

Michael Aviram, DSc
Authors : Shamir R, Hartman C, Karry R, Pavlotzky E, Eliakim R, Lachter J, Suissa A, Aviram M.

Free Radic Biol Med. 2005 Aug 1;39(3):336-44. Epub 2005 Apr 6. PMID: 15993332 [PubMed – indexed for MEDLINE]

Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences.

2005

Michael Aviram, DSc
Authors : Aviram M, Rosenblat M.

Curr Opin Lipidol. 2005 Aug;16(4):393-9. Review. PMID: 15990587 [PubMed – indexed for MEDLINE]

Effect of obesity on the relationship between plasma C-reactive protein and coronary artery stenosis in patients with stable angina

2005

Rafael Beyar, MD, DSc
Authors : Aronson D, Goldberg A, Roguin A, Petcherski S, Rimer D, Gruberg L, Avizohar O, Levy Y, Markiewicz W, Beyar R.

Atherosclerosis. 2006 Mar;185(1):137-42. Epub 2005 Jul 15. PMID: 16024024 [PubMed – indexed for MEDLINE]

Increased renal hypertrophy in diabetic mice genetically modified at the haptoglobin locus.

2005

Andrew Levy, MD, PhD
Authors : Miller-Lotan R, Herskowitz Y, Kalet-Litman S, Nakhoul F, Aronson D, Zoabi R, Asaf R, Ben-Izhak O, Sabo E, Lim SK, Baumann H, Berger FG, Levy AP.

Diabetes Metab Res Rev. 2005 Jul-Aug;21(4):332-7.

Oxidative stress in arteriogenic erectile dysfunction: prophylactic role of antioxidants.

2005

Michael Aviram, DSc
Authors : Azadzoi KM, Schulman RN, Aviram M, Siroky MB.

J Urol. 2005 Jul;174(1):386-93. PMID: 15947695 [PubMed – indexed for MEDLINE]

Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice

2005

Michael Aviram, DSc
Authors : Rozenberg O, Shih DM, Aviram M.

Atherosclerosis. 2005 Jul;181(1):9-18. PMID: 15939049 [PubMed – indexed for MEDLINE]

Differentiation pathways in human embryonic stem cell-derived cardiomyocytes.

2005

Lior Gepstein, MD, PhD
Authors : Lev S, Kehat I, Gepstein L.

Ann N Y Acad Sci. 2005 Jun;1047:50-65. Review. PMID: 16093484 [PubMed – indexed for MEDLINE]

From organ to molecules: steps and consequences.

2005

Rafael Beyar, MD, DSc
Authors : Beyar R.

Ann N Y Acad Sci. 2005 Jun;1047:1-12. Review. PMID: 16093480 [PubMed – indexed for MEDLINE]

The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.

2005

Rafael Beyar, MD, DSc
Authors : Lavi S, Gruberg L, Kapeliovich M, Hammerman H, Boulos M, Grenadier E, Aronson D, Markiewicz W, Beyar R.

J Invasive Cardiol. 2005 Jun;17(6):296-9. PMID: 16003002 [PubMed – indexed for MEDLINE]

Paraoxonase 1 (PON1) is present in postprandial chylomicrons.

2005

Michael Aviram, DSc
Authors : Fuhrman B, Volkova N, Aviram M.

Atherosclerosis. 2005 May;180(1):55-61. Epub 2005 Jan 15. PMID: 15823275 [PubMed – indexed for MEDLINE]

Usefulness of electroanatomical mapping to differentiate between right ventricular outflow tract tachycardia and arrhythmogenic right ventricular dysplasia.

2005

Lior Gepstein, MD, PhD
Authors : Boulos M, Lashevsky I, Gepstein L.

Am J Cardiol. 2005 Apr 15;95(8):935-40. PMID: 15820158 [PubMed – indexed for MEDLINE

Gap junctional remodeling by hypoxia in cultured neonatal rat ventricular myocytes.

2005

Ofer Binah, PhD
Authors : Zeevi-Levin N, Barac YD, Reisner Y, Reiter I, Yaniv G, Meiry G, Abassi Z, Kostin S, Schaper J, Rosen MR, Resnick N, Binah O.

Cardiovasc Res. 2005 Apr 1;66(1):64-73. PMID: 15769449 [PubMed – indexed for MEDLINE]

Grape powder polyphenols attenuate atherosclerosis development in apolipoprotein E deficient (E0) mice and reduce macrophage atherogenicity.

2005

Michael Aviram, DSc
Authors : Fuhrman B, Volkova N, Coleman R, Aviram M.

J Nutr. 2005 Apr;135(4):722-8. PMID: 15795424 [PubMed – indexed for MEDLINE]

Prospective motion correction of X-ray images for coronary interventions.

2005

Rafael Beyar, MD, DSc
Authors : Shechter G, Shechter B, Resar JR, Beyar R.

IEEE Trans Med Imaging. 2005 Apr;24(4):441-50. PMID: 15822802 [PubMed – indexed for MEDLINE]

Haptoglobin genotype- and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo.

2005

Andrew Levy, MD, PhD
Authors : Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP.

Circ Res. 2005 Mar 4;96(4):435-41.

Angiogenesis – an update.

2005

Andrew Levy, MD, PhD
Authors : Roguin A, Levy AP.

Pediatr Endocrinol Rev. 2005 Mar;2(3):391-8. Review.

Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine.

2005

Michael Aviram, DSc
Authors : Rosenblat M, Vaya J, Shih D, Aviram M.

Atherosclerosis. 2005 Mar;179(1):69-77. Epub 2004 Dec 29. PMID: 15721011 [PubMed – indexed for MEDLINE]

Impact of body mass index on the outcome of patients with multivessel disease randomized to either coronary artery bypass grafting or stenting in the ARTS trial: The obesity paradox II?

2005

Rafael Beyar, MD, DSc
Authors : Gruberg L, Mercado N, Milo S, Boersma E, Disco C, van Es GA, Lemos PA, Ben Tzvi M, Wijns W, Unger F, Beyar R, Serruys PW; Arterial Revascularization Therapies Study Investigators.

Am J Cardiol. 2005 Feb 15;95(4):439-44. PMID: 15695125 [PubMed – indexed for MEDLINE]

Haptoglobin phenotype, sleep-disordered breathing, and the prevalence of cardiovascular disease: the Sleep Heart Health Study.

2005

Andrew Levy, MD, PhD
Authors : Levy AP, Zhang L, Miller-Lotan R, Redline S, O’Connor GT, Quan SF, Resnick HE.

Sleep. 2005 Feb 1;28(2):207-13.

New horizons for VEGF. Is there a role for nuclear localization?

2005

Andrew Levy, MD, PhD
Authors : Lejbkowicz F, Goldberg-Cohen I, Levy AP.

Acta Histochem. 2005;106(6):405-11.

Cerebral embolic protection devices and percutaneous carotid artery stenting.

2005

Rafael Beyar, MD, DSc
Authors : Gruberg L, Beyar R.

Int J Cardiovasc Intervent. 2005;7(3):117-21. Review. No abstract available. PMID: 16243731 [PubMed – indexed for MEDLINE]

Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development.

2005

Michael Aviram, DSc
Authors : Aviram M, Kaplan M, Rosenblat M, Fuhrman B.

Handb Exp Pharmacol. 2005;(170):263-300. Review. PMID: 16596803 [PubMed – indexed for MEDLINE]

Functional properties of human embryonic stem cell-derived cardiomyocytes.

2005

Ofer Binah, PhD
Authors : Dolnikov K, Shilkrut M, Zeevi-Levin N, Danon A, Gerecht-Nir S, Itskovitz-Eldor J, Binah O.

Ann N Y Acad Sci ;1047:66-75.

Haptoglobin genotypeand diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo.

2005

Andrew Levy, MD, PhD
Authors : Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP.

Circ Res ;96:435-441.

Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction.

2005

Andrew Levy, MD, PhD
Authors : Suleiman M, Aronson D, Asleh R, Kapeliovich MP, Roguin A, Meisel SR, Shochat M, Sulieman A, Reisner SA, Markiewicz W, Hammerman H, Lotan R, Levy NS, Levy AP.

Diabetes ; 54:2802-2806.

In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease.

2005

Andrew Levy, MD, PhD
Authors : Asleh R.

Vasc Health Risk Manag. 2005;1(1):19-28.

Read the Article:

Placental TFPI is decreased in gestational vascular complications and can be restored by maternal enoxaparin treatment.

2005

Benjamin Brenner, MD
Authors : Aharon A, Lanir N, Drugan A, Brenner B.

J Thromb Haemost;3:10-2355.

Clinical management of thrombophilia-related placental vascular complications.

2004

Benjamin Brenner, MD
Authors :

Blood ;103:4003-4009.

Coagulation, inflammation, and pregnancy complications.

2004

Benjamin Brenner, MD
Authors : Sarig G, Brenner B.

Lancet ;363:96-97.

Electromechanical integration of cardiomyocytes derived from human embryonic stem cells.

2004

Lior Gepstein, MD, PhD
Authors : Kehat I, Khimovich L, Caspi O, Gepstein A, Shofti R, Arbel G, Huber I, Satin J, Itskovitz-Eldor J, Gepstein L.

Nat Biotechnol ;22:1282-1289.

Novel approaches to reduce restenosis

2004

Rafael Beyar, MD, DSc
Authors : Beyar R.

Ann N Y Acad Sci ; 1015:367-378.

Paraoxonases 1, 2, and 3, oxidative stress,and macrophage foam cell formation during atherosclerosis development.

2004

Michael Aviram, DSc
Authors : Aviram M, Rosenblat M.

Free Radic Biol Med ;37:1304-1316.

Large a-v fistula: pathophysiologic consequences and therapeutic perspectives

2003

Aaron Hoffman, MD
Authors : Abassi, Z., Winaver, J., Hoffman, A.

Curr Vasc Pharmacol 1, 347-354.

Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation.

2003

Michael Aviram, DSc
Authors : Rozenberg O, Shih DM, Aviram M.

Arterioscler Thromb Vasc Biol ;23:461-467.

Effects of endothelin receptors ET_A and ET_B blockade on renal haemodynamics in normal rats and in rats with experimental congestive heart failure

2002

Aaron Hoffman, MD
Authors : Abassi, Z., Francis, B., Wessale, J., Ovcharenko, E., Winaver, J., Hoffman, A.

Clin Sci 103, 245S-248S.

Electrophysiological modulation of cardiomyocytic tissue by transfected fibroblasts expressing potassium channels: a novel strategy to manipulate excitability.

2002

Lior Gepstein, MD, PhD
Authors : Feld Y, Melamed-Frank M, Kehat I, Tal D, Marom S, Gepstein L.

Circulation ;105:522-529.

Anti-atherogenicity of nutritional antioxidants

2001

Michael Aviram, DSc
Authors : Fuhrman B, Aviram M.

IDrugs. 2001 Jan;4(1):82-92. PMID: 16034706 [PubMed]

Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes.

2001

Lior Gepstein, MD, PhD
Authors : Kehat I, Kenyagin-Karsenti D, Snir M, Segev H, Amit M, Gepstein A, Livne E, Binah O, Itskovitz-Eldor J, Gepstein L.

J Clin Invest ;108:407-414.

Mechanisms of big endothelin-1-induced diuresis and natriuresis: role of ET_B receptors

2000

Aaron Hoffman, MD
Authors : Hoffman, A., Abassi, Z. A., Brodsky, S., Ramadan, R., Winaver, J.

Hypertension 35, 732-739.

Haptoglobin phenotype and vascular complications in patients with diabetes.

2000

Andrew Levy, MD, PhD
Authors : Levy AP, Roguin A, Hochberg I, Herer P, Marsh S, Nakhoul FM, Skorecki K.

N Engl J Med ;343:969-970.

Effect of low altitude at the Dead Sea on exercise capacity and cardiopulmonary response to exercise in cystic fibrosis patients with moderate to severe lung disease.

1900

Michael Aviram, DSc
Authors : Falk B, Nini A, Zigel L, Yahav Y, Aviram M, Rivlin J, Bentur L, Avital A, Dotan R, Blau H.

Pediatr Pulmonol. 2006 Mar;41(3):234-41. PMID: 16429430 [PubMed – in process]

Read Full Post »

Host – Tumor Interactions during Cancer Therapy – Dr. Yuval Shaked’s Lab @Technion

Posted in CANCER BIOLOGY & Innovations in Cancer Therapy, Human Immune System in Health and in Disease, Innovation in Immunology Diagnostics on May 27, 2014| Leave a Comment »

Host – Tumor Interactions during Cancer Therapy – Dr. Yuval Shaked’s Lab @Technion

Reporter: Aviva Lev-Ari, PhD, RN

Yuval Shaked, PhD

Publications by Yuval Shaked, PhD

Assistant Professor of Molecular Pharmacology
PhD, 2004 – Hebrew University, Israel

Figure Legend:

Anti-cancer therapy affects both the host and the tumor. Host cells or factors home to the treated tumor microenvironment and promote tumor growth and even spread of metastasis. Blocking such therapy-induced tumor effects can improve treatment outcome.

Publications

Publications by Author The Ubiquitin System and Cellular Protein Turnover and Interactions Immunity and Host Defense Cardiovascular Biology The Central Nervous System in Health and Disease Genetics Developmental Biology and Cancer Research

Understanding host – tumor interactions during cancer therapy

Representative publications

Benayoun L, Gingis-Velitski S, Voloshin T, Segal E, Segev R, Munster M, Bril R, Satchi-Fainaro R, Scherer SJ, Shaked Y. 2012. Tumor initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs. Stem Cells 30, 1831-41.

Gingis-Velitski S, Loven D, Benayoun L, Munster M, Bril R, Voloshin T, Alishekevitz D, Bertolini F, Shaked Y. 2011. Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. Cancer Research 71, 6986-96.

Voloshin T, Gingis-Veltski S, Milsom C, Man S, Munster M, Kerbel RS, Shaked Y. 2011. G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. Blood 118, 3426-35.

Email:	yshaked@tx.technion.ac.il

Publications by Yuval Shaked, PhD

Tumor-derived microparticles induce bone marrow-derived cell mobilization and tumor homing: A process regulated by osteopontin

2013

Yuval Shaked, PhD
Authors : Fremder E, Munster M, Aharon A, Miller V, Gingis-Velitski S, Voloshin T, Alishekevitz D, Bril R, Scherer SJ, Loven D, Brenner B, Shaked Y.

Int J Cancer. 2013 Dec 18. doi:10.1002/ijc.28678. [Epub ahead of print] PubMed PMID: 24347266.

Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer

2013

Yuval Shaked, PhD
Authors : Loven D, Hasnis E, Bertolini F, Shaked Y.

Drug Discov Today. 2013 Feb;18(3-4):193-201.

Differential therapeutic effects of anti-VEGF-A antibody in different tumor models: implications for choosing appropriate tumor models for drug testing.

2013

Yuval Shaked, PhD
Authors : Alishekevitz D, Bril R, Loven D, Miller V, Voloshin T, Gingis-Velitski S, Fremder E, Scherer SJ, Shaked Y.

Mol Cancer Ther. 2013 Oct 22. [Epub ahead of print] PubMed PMID: 24150126.

Poly(ethylene glycol)-paclitaxel-alendronate self-assembled micelles for the targeted treatment of breast cancer bone metastases

2013

Yuval Shaked, PhD
Authors : Miller K, Clementi C, Polyak D, Eldar-Boock A, Benayoun L, Barshack I, Shaked Y, Pasut G, Satchi-Fainaro R.

Biomaterials. 2013 May;34(15):3795-806.

In vitro enrichment of tumor-initiating cells from human established cell lines.

2013

Yuval Shaked, PhD
Authors : Benayoun L, Shaked Y.

Curr Protoc Stem Cell Biol. 2013 Feb;Chapter 3:Unit 3.7. doi: 10.1002/9780470151808.sc0307s24. PubMed PMID: 23404675.

Tumor initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs

2012

Yuval Shaked, PhD
Authors : Benayoun L, Gingis-Velitski S, Voloshin T, Segal E, Segev R, Munster M, Bril R, Satchi-Fainaro R, Scherer SJ, Shaked Y.

Stem Cells 30, 1831-41.

Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in Mice.

2011

Yuval Shaked, PhD
Authors : Gingis-Velitski S, Loven D, Benayoun L, Munster M, Bril R, Voloshin T,

Cancer Res. 2011 Nov 15;71(22):6986-96.

G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist.

2011

Yuval Shaked, PhD
Authors : Voloshin T, Gingis-Velitski S, Bril R, Benayoun L, Munster M, Milsom C, Man S,

Blood. 2011 Jun 17. 118(12):3426-35.

Antiangiogenic Antitumor Activity of HPMA Copolymer-Paclitaxel-Alendronate Conjugate on Breast Cancer Bone Metastasis Mouse Model.

2011

Yuval Shaked, PhD
Authors : Miller K, Eldar-Boock A, Polyak D, Segal E, Benayoun L, Shaked Y, Satchi-Fainaro R.

Mol Pharm. 2011 May 17. [Epub ahead of print]

Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances.

2011

Yuval Shaked, PhD
Authors : Kopeckova P, Shaked Y, Kopecek J, Satchi-Fainaro

Biomaterials. 2011 Mar 21. 32(19):4450-63.

The angiogenic profile of colorectal cancer patients following open or laparoscopic colectomy.

2010

Yuval Shaked, PhD
Authors : Voloshin T, Gingis-Velitski S, Shaked Y.

Cancer Biol Ther. 2010 Nov 10;10(7):686-8.

Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab

2009

Yuval Shaked, PhD
Authors : Calleri A‭, ‬Bono A‭, ‬Bagnardi V‭, ‬Quarna J‭, ‬Mancuso P‭, ‬Rabascio C‭, ‬Dellapasqua S‭,‬ Campagnoli E‭, ‬Shaked Y‭, ‬Goldhirsch A‭, ‬Colleoni M‭, ‬Bertolini F‭.

Clin Cancer Res‭. ‬2009‭ ‬Dec 15‭;‬15‭(‬24‭):‬7652-7657‭

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents

2009

Yuval Shaked, PhD
Authors : Shaked Y, Tang T, Woloszynek J, Daenen LG, Man S, Xu P, Cai SR, Arbeit JM, Voest EE, Chaplin DJ, Smythe J, Harris A, Nathan P, Judson I, Rustin G, Bertolini F, Link DC, Kerbel RS.

Cancer Res. 2009 69:7524-8.

Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil?

2009

Yuval Shaked, PhD
Authors : Shaked Y, Voest EE.

Biochim Biophys Acta. 2009 1796(1):1-4.

Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents

2008

Yuval Shaked, PhD
Authors : Shaked, Y., Henke, E., Roodhart, J. M. L., Mancuso, P., Langenberg, M. H. G., Colleoni, M., Daenen, L. G., Man, S., Xu, P., Emmenegger, U., Tang, T., Zhu, Z., Witte, L., Streiter, R. M., Bertolini, F., Voest, E. E., Benezra, R., Kerbel, R. S.

Cancer Cell 14, 263-273.

Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy

2007

Yuval Shaked, PhD
Authors : Shaked, Y., Kerbel, R. S.

Cancer Res 67, 7055-7058.

Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors

2006

Yuval Shaked, PhD
Authors : Shaked, Y., Ciarrocchi, A., Franco, M., Lee, C. R., Man, S., Cheung, A. M., Hicklin, D. J., Chaplin, D., Foster, F. S., Benezra, R., Kerbel, R. S.

Science 313, 1785-1787.

Read Full Post »

Older Posts »

Archive for May, 2014

Bristol-Myers Squibb ($BMY): Leading Risk Taker on a estimated $1.3 Billion Committed to Fund 78 currently known Clinical Trials which will enroll 19,000 Cancer Patients

American Society of Clinical Oncology — History

History Article Series

J&J expands prostate cancer program with cancer vax tech from Aduro

Bristol-Myers Squibb: It’s all about the ‘breakthrough’ drug nivolumab now

Share this:

Like this:

Two new possible Drug Targets for Triple Negative Breast Cancer: The genes, MLF2 (myeloid leukemia factor 2) and RPL39 (a ribosomal protein) have roles in Angiogenesis

Cornell University Scientists discover two new possible drug targets for triple negative breast cancer

Learn which HER2-positive breast cancer treatment may be right for you

Other related articles published in this Open Access Online Scientific Journal include the following:

Share this:

Like this:

ipilimumab, a Drug that blocks CTLA-4 Freeing T cells to Attack Tumors @DM Anderson Cancer Center

The immune system connection

Study results consistent with failed clinical trial

Supportive tumor tissue surrounding cancer cells hinders, rather than helps, pancreatic cancer

Study shows fibrosis summons an immune attack, challenges theory that it blocks chemotherapy

Share this:

Like this:

EmergingMed has guided more than 170,000 patients through a search for Cancer Clinical Trials

Search Online

Share this:

Like this:

Cancer Labs at School of Medicine @ Technion

Research Groups

SOURCE

Yuval Shaked, PhD

Assistant Professor of Molecular Pharmacology

Understanding host – tumor interactions during cancer therapy

Other Related articled published on this Open Access Online Scientific Journal included the following:

Share this:

Like this:

Levels of Tumor-associated Gene Expression & Cancer Biomarkers: OncoCyte’s PanC-Dx Diagnostic Tests of Cornell Medical College Blood Samples derived from Healthy and Lung Cancer Patients

OncoCyte, Cornell Collaborate on Lung Cancer Dx

Related Stories

Share this:

Like this:

Asymptomatic Patients After Percutaneous Coronary Intervention: Low Yield of Stress Imaging – Population-Based Study

Low Yield of Stress Imaging in a Population-Based Study of Asymptomatic Patients After Percutaneous Coronary Intervention

Abstract

Share this:

Like this:

Immunity and Host Defense – A Bibliography of Research @Technion

Share this:

Like this:

Cardiovascular Biology – A Bibliography of Research @Technion

Share this:

Like this:

Host – Tumor Interactions during Cancer Therapy – Dr. Yuval Shaked’s Lab @Technion

Yuval Shaked, PhD

Assistant Professor of Molecular Pharmacology

Figure Legend:

Understanding host – tumor interactions during cancer therapy

Representative publications

Share this:

Like this:

Follow Blog via Email

Recent Posts

Archives

Categories

Meta